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ABSTRACT
In this dissertation, we have designed a series of recombinant fluorescent full-length
protease substrates containing the cleavage sites separated by a biotinylation tag and a
GFP domain, which can be associated with streptavidin-coated microspheres/nanospheres.
We have developed microsphere-based platforms to detect the cleavage activities of
several proteases simultaneously. In addition, we have performed high-throughput
screening (HTS) to identify potential inhibitors for the Bacillus anthracis lethal factor
protease (LF) and the Botulinum neurotoxin type A & F light chain proteases (BoNT/A
& F LC). In order to select the efficient inhibitors, a chemical library of 350,000
compounds was screened with the HyperCyt® high-throughput flow cytometry system,
which can screen thousands of compounds per day for drug discovery. In order to
understand the kinetic mechanisms of these proteases as well as the inhibitory
mechanisms of some inhibitor candidates, we have carried out surface-based analysis to
characterize the enzymatic reaction in terms of the key kinetic parameters of BoNT/A LC
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(Km, kcat etc.) for surface-bound substrates by flow cytometry. In my work, we have also
created a FRET full-length substrate solution assay to determine the kinetic constants of
the proteases and inhibitory mechanisms of some known inhibitors. However, despite the
advantages of the microsphere-based assay, the surface area to volume ratio of
microspheres limits us to sub-saturating concentrations of substrate (in the low nM range).
Therefore, we developed a nanosphere-based protease assay platform to increase
substrate concentrations. To demonstrate this approach, we have implemented our
nanosphere-based protease assay using the toxin protease models to prove the concept.
The surface-based system is a promising method for the use of multiple protease assays
to evaluate the kinetic mechanisms and to select inhibitors for several different proteases
simultaneously. This provides the advantages of robustness, sensitivity, low substrate
cost and reproducibility.
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Chapter 1
Introduction
1.1 Bacterial Zinc Dependent Metalloproteases
Proteases are of great interest as possible drug targets, because they regulate many
physiological processes including infection, cell growth and death, fertilization,
inflammation, allergic reactions, bone remodeling, tumor growth and blood clotting.1
Bacterial proteases are critical to the toxicity of many pathogens as they commonly target
host pathways that lead to the death of the host organism.2 Therefore, the development of
novel drugs and antibiotics that target bacterial protease is of great importance.3 At
present, there are five catalytic types of bacterial proteases that have been recognized.
Four are based on the type of amino acid found at the active site (serine, threonine,
cysteine, or aspartate), while the fifth type coordinates a metal ion in its active site.2
These metalloproteases (MPRs) are specific proteases use coordinated metal ions to
attack the peptide bond to cleave proteins. The metal ion is usually zinc, cobalt, or
manganese.2 Generally, MPRs are divided into two groups depending on how many
metal ions are required in the catalytic mechanism. So far, most MPRs are one-metal-iondependent proteases, with the exception of some exopeptidases that require two catalytic
metal ions for efficient cleavage.2, 4 MPRs are widely used by bacteria and play various
pathogenic roles in infection.5,6 For example, some bacteria use MPRs to process
enterotoxin (e.g. cholera toxin) to their active state. Other bacteria use proteases as part of
their toxins, which is the case for the Botulinum neurotoxins (BoNT) and Tetanus
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neurotoxins (TeNT) that use MPRs to directly cleave target host proteins.7,8 For these
reasons, MPRs are important targets for therapeutic compounds.
Most MPRs are zinc-dependent proteases and are integral to virtually all aspects of
metabolism.9 The consensus binding motif for zinc-containing metalloproteases is
HEXXH, in which two histidine residues coordinate zinc divalent cationic binding.10 This
zinc-binding motif has been found in the light chain of Clostridium Botulinum
neurotoxins11, Bacteroides fragilis enterotoxin12, and Bacillus anthracis lethal factor13.
These light chain proteases require the presence of zinc for activity.10 Of specific interest
to this work, Botulinum neurotoxin (BoNT) light chains cleave one of three soluble Nethylamaleimide-sensitive factor-attachment protein receptor (SNARE) proteins that are
components of the neuroexocytosis machinery. Cleavage of these proteins leads to the
blockade of neurotransmitter release and consequent paralysis.14 The light chain of
Bacillus anthracis lethal toxin, known as lethal factor (LF) cleaves the mitogen-activated
protein kinase-kinases (MAPKKs) at their amino-terminus.14 Though the toxicity of
many bacterial toxins are due to the Zn metalloproteases activity, the Zn coordinating
active site is highly conserved across many families of zinc metalloproteases. This makes
it difficult to target the active site of toxin MPRs, as the numerous cellular Zn
metalloproteases, such as matrix metalloprotease (MMPs) and metalloproteases with a
disintegrin domain (ADAM) are critical for cell processes. Therefore, understanding the
structure-activity relationships of these enzymes would be beneficial for the development
of potential inhibitors. In addition, a further understanding of the mechanism of these
enzymes will offer great opportunity to screen for or create new and useful protease
compounds that specifically target toxin MPRs.
2
	
  

1.2 Botulinum Neurotoxins
Botulinum neurotoxins (BoNTs) are the most toxic substance known.15,16 They are
produced by Clostridium botulinum.17,18,19 Each BoNT serotype is a two-chain holotoxin
made up of two polypeptides with a molecular weight of 150 kDa, which is modified
post-translationally by bacterial or host protease. This precursor protein is composed of a
subunit of one 100 kDa heavy chain (HC) subunit linked to a 50 kDa light chain (LC)
subunit by an essential interchain disulfide bridge and a poorly structured protein
segment, called the belt, which extends from the HC to LC.7,20 The HC is a binding
domain containing two unique subdomains, the NH2-terminal half (HC-N) and the Cterminal half (HC-C), with few protein-protein contacts between one and another. HC-N is
composed of a jelly-roll motif arranged with two seven-stranded β-strands while HC-C
embraces a modified β-trefoil folding motif for recognition and binding functions.7 The
LC at the N-terminal is a zinc-dependent metalloprotease that cleaves the protein
substrates.21 The LC itself is nontoxic and inhibits exocytosis while direct microinjection
of the LC into the cytosol causes blockage of membrane exocytosis.22,23
BoNTs exist as seven serologically distinct isoforms (denoted A to G). All BoNTs (AG) inhibit signaling at nerve terminals leading to the symptoms of botulism.7 The release
of acetylcholine at the neuromuscular junction, is mediated by the soluble Nethylamaleimide-sensitive factor-attachment protein receptor (SNARE) proteins that
allow the membrane of the synaptic vesicle containing acetylcholine to fuse with the
neuronal cell membrane. The two-part botulinum neurotoxin binds to the neuronal cell
membrane via its heavy chain and enters the neuron by endocytosis. Once inside the cell,
the light chain cleaves at specific sites on the SNARE proteins, preventing complete
3
	
  

assembly of the synaptic fusion complex and thereby blocking acetylcholine release
(Figure 1.1).24 BoNTs cleave the SNARE proteins that include synaptobrevin (or vesicle
associated membrane protein; VAMP), the 25 kDa synaptosomal-associated protein
(SNAP-25), and syntaxin.7 Specifically, BoNT/A, BoNT/C and BoNT/E cleave SNAP-25
at different peptide bonds; BoNT/B, BoNT/D, BoNT/F and BoNT/G cleave VAMP; and,
BoNT/C cleaves syntaxin (Figure 1.1).7 The specific cleavage sites of each BoNT
serotype are shown in Table 1.1. Several clinical types of human botulism have been
identified that are caused by BoNT/A, BoNT/B, BoNT/E, and occasionally BoNT/F.24
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Figure 1.1 Mechanism of action of BoNTs. BoNT heavy chain binds to the neuronal cell
at the nerve terminus and transfers the light chain to cleave SNARE proteins so that the
SNARE complex does not form and the membranes do not fuse. This figure is modified
from reference 24.
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Table 1.1 The cleavage sites of each BoNT serotype on SNARE proteins.
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1.2.1

BoNT/A Cleaves SNAP-25

Botulinum neurotoxin type A (BoNT/A), which cleaves SNAP-25, is the most frequent
cause of human botulism.24 SNAP-25 regulates vesicle exocytosis and belongs to the
SNARE superfamily of small membrane proteins, which anchor to the cytosolic surface
of membranes through palmitoyl side chains, located in the central domain of the
molecule. SNAP-25 is composed of two α-helices that form the exocytotic fusion
complex with syntaxin-1 and synaptobrevin, all of which are required for vesicle
fusion.25,26 In addition, SNAP-25 provides an essential mechanism for triggering Ca2+dependent membrane fusion and controlling fusion pore dynamics during the final steps
of exocytosis by interacting with the synaptic vesicle protein synaptotagmin I.27,28
Therefore, SNAP-25 has been considered as a multifunctional protein that controls
neurotransmitter secretion via several interactions.
To cleave SNAP-25, BoNT/A inserts into the vesicle and undergoes a pH-dependent
conformational change that causes the dissociation of the heavy and light chains and an
increase of the toxin’s hydrophobicity.29 BoNT/A recognizes the highly conserved
SNARE motif that is found four times (S1-S4) within the SNAP-25 molecule.30 BoNT/A
requires the presence of the C-terminal region of SNAP-25 including the S4 site, while
the three N-terminal sites (S1-S3) are not required (Figure 1.2).31 BoNT/A recognizes its
substrate via both a structural motif and the sites containing the peptide bond to be
cleaved.32 The activity of BoNT/A LC is strongly influenced by distal substitutions and
deletions.33,34
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Figure 1.2 BoNT/A cleaves SNAP-25 at a specific site as shown by the arrow. The
binding motifs are denoted by boxes at C-terminal (S4) and N-terminal (S1-S3) regions.
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The exosites are distant from the cleavage sites and play crucial roles in efficient
substrate recognition and cleavage of light chain.32 The concept that a distant binding site
is necessary for efficient cleavage of SNAP-25 was supported by co-crystal structures of
a truncated SNAP-25 bound to BoNT/A. This showed that there was a distant binding
site required for BoNT/A binding.35 This site overlaps the S4 site and likely represents
the same interaction point noted in both studies.31,35 The significant structural changes
near the toxin’s catalytic pocket upon substrate binding may serve to render the protease
competent for catalysis.35 Understanding the binding mechanism of BoNT/A and SNAP25 at the distal site may provide insight into a modification of BoNT/A that would
optimize therapeutic potential as well as develop serotype-specific inhibitors against
botulism.36 Importantly, inhibitors that target the distal site are likely to be very specific
to a BoNT serotype and less likely to target host MPRs, which could be expected to
reduce compound toxicity.

1.2.2

BoNT/F Cleaves VAMP-2

Botulinum neurotoxin type F is a zinc-endopeptidase with a unique specificity for
VAMP/synaptobrevin, which is an essential component of SNARE proteins for the
exocytosis apparatus.37 VAMP is a tail-anchored membrane protein of exocytotic
vesicles38 and is composed of different isoforms.39 Neurotoxin-insensitive isoforms are
present in many non-neuronal tissues.40,41 Clostridial neurotoxins lack activity on nonneuronal cells because they do not bind to these cells that lack cell surface neurotoxin
receptors.37 Three isoforms have been identified containing VAMP-1 and VAMP-2
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present in the neural and neuroendocrine tissues,42 and a third, cellubrevin, which is
presence in non-neuronal cells.43 BoNT/F can cleave both VAMP-1 and VAMP-2.
VAMP-1 is preferentially expressed in the motor system, whereas VAMP-2 is
predominantly present in nuclei associated with sensory and integrative functions.42,44
BoNT/F cleaves VAMP-2 within a conserved region containing the cleavage sites, and
the recognition sites (V1 and V2).32 BoNT/F cleaves the peptide bond Gln58-Lys59,
which is located between V1 and V2 (Figure 1.3). Mutation studies verify that both V1
and V2 play major roles in BoNT/F activity.37 So far, only a few mechanistic studies of
BoNT/F have been published, but very few inhibitors of BoNT/F have been reported. It is
of great importance to research and identify inhibitors for BoNT/F in order to treat human
botulism. Because BoNT/F LC is nontoxic, it has been the main target for in vitro assays
to identify potential inhibitors. In addition, the mechanistic study of full-length substrate
containing distal sites will provide a great platform to design potential inhibitors and
modify the protease analogues for clinical therapy. Again, targeting the distal sites (V1
and V2) may offer a path to the development of highly specific inhibitors that have
reduced cellular toxicity.
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Figure 1.3 BoNT/F cleaves VAMP-2 with two binding sites V1 and V2.
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1.3 Anthrax Lethal Factor
Bacillus anthracis is a gram-positive, aerobic, spore-forming, rod-shaped bacterium,
which causes Anthrax.45 This disease is initiated by the entry of spores into the body of
the host causing three types of infections. They are cutaneous, gastrointestinal and
inhalational, which can occur via a minor abrasion, an insect bite, or by eating
contaminated meat or inhaling airborne spores.46 B. anthracis has long been of concern as
a potential agent of biological warfare.47 B. anthracis is composed of two virulence
factors that are the gamma-linked, the poly-D-glutamic acid capsule and the secreted
anthrax toxin.48 Anthrax toxin is composed of three proteins that are termed protective
antigen (PA), lethal factor (LF) and edema factor (EF).49 Each of the three components is
individually non-toxic.47 The combination of PA and LF produces lethal toxin (LT)
whereas the combination of PA and EF produces edema toxin (ET). Both toxins are
sufficient to produce many of the symptoms of anthrax infection.50,51 LT is a binary toxin
consisting of a binding moiety (PA) and an enzymatic moiety (LF). PA binds to toxin
receptors on the surface of the host cell and is subsequently processed by the host enzyme
furin.52,53 Then a seven-member ring oligomer is formed which can bind up to three
molecules of LF. The resulting toxin complex is endocytosed and trafficked to an acidic
compartment where the low pH triggers a conformational change in PA that promotes
membrane insertion and translocation of LF into the cytosol (Figure 1.4).54

12
	
  

Figure 1.4 Entry and action of anthrax lethal toxin (LT). PA binds to its receptor
(ANTXR) and is cleaved by furin to form a seven-member ring oligomer, which binds up
to three LF molecules. The resulting toxin complex is endocytosed and trafficked to an
acidic compartment, low pH triggers a conformational change in PA that promotes
membrane insertion and translocation of LF into the cytosol for cleavage of MAPKK
proteins. This figure is modified from reference 54.
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LF is a 90 kDa zinc-dependent metalloprotease that cleaves mitogen-activated protein
kinase kinase (MAPKK) isotypes 1-4 and 6-7.55,56 LF is an elongated protein (>10 nm)
comprised of four partially related domains containing: 1) a N-terminal PA-binding
domain of EF, 2) a domain involved in binding to residues in MAPKK substrates distant
from the cleavage site, 3) an inserted helical domain involved in binding to substrates,
and 4) a catalytic domain related to Clostridial neurotoxins.57 LF cleaves the peptide
bond within the N-terminal proline-rich region that precedes the kinase domain of the
substrates by disrupting the protein interaction involved in assembling signaling
complexes, thus preventing MAPKK activation, leading to the death of the host via a
poorly defined sequence of events.58 Therefore, treatment with LT-caused disease is of
great importance, because the MAPKK pathway is a key regulatory signal transduction
pathway that sends signals from the cell surface to intracellular effectors through a
cascade of phosphorylation events.59
Anthrax is a complex toxin and fully effective treatment may require complementary
approaches. It would be of great interest to design therapeutics targeting the clinical
effects of the toxins because the consequences of LF activity and downstream of
proteolytic cleavage of MAPKKs may lead to the death of the host.46

1.4 Protease Inhibitors
Potential protease inhibitors are emerging with promising therapeutic uses in the
treatment of diseases including cancer,60 infections,61,62 as well as inflammatory,
immunological, respiratory, and neurodegenerative disorders.63,64,65 A potential inhibitor
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must be not only highly selective in binding to a particular protease, but must also have
appropriate pharmacokinetic and pharmacodynamic properties. Protease inhibitors have
been widely developed by screening natural products to identify lead compounds. Varied
methods have been developed for subsequent optimization of these lead compounds or
the substrates,66 which include truncating polypeptide substrates to short peptides,
replacing the cleavable amide bond by a noncleavable isostere, and optimizing inhibitor
potency via structural modifications.67
Typically, all known metalloproteases are zinc-dependent proteases that use a zinc
atom to affect amide bond hydrolysis. The zinc ion is generally tetrahedral-coordinated to
three donor groups from the enzyme and a water molecule.67 Therefore, the inhibitors
blocking this coordination have been widely designed and synthesized as metalloprotease
inhibitors. Since many metalloproteases from the same protein families share a common
active site architecture, compounds designed to inhibit one protease could be used as
inhibitors of the other proteases by virtue of their complementary specificity.68
Unfortunately, the cross reactivity of many inhibitors also leads to a great deal of off
target toxicity for metalloprotease inhibitors.69 Thus, there is a great need for screening
approaches that result in specific inhibitors that do not target the highly conserved active
site.

1.4.1

Botulinum Neurotoxin Inhibitors

Many current research efforts seek to identify BoNT protease inhibitors, as
metalloprotease activity is critical to the function of the toxin.70 Many approaches have
15
	
  

been envisioned for inhibitor development including mimicking peptide sequences based
upon the native SNARE protein substrate or identifying small molecules that bind to the
toxin and inactivate it.70 Several effective inhibitors have been reported based upon
peptide scaffolds.71,72,73 Given the presence of zinc ion in the LC active site, the
hydroxamate zinc-binding functionality when coupled to a suitable scaffold to impart
specificity, would seem to provide a promising platform for potent BoNT inhibitors.
However, directly targeting the highly conserved active site may lead to cross reactivity
to other MPRs, which may lead to compound side effects. Nonetheless, the use of heavymetal chelators has been considered for potential therapeutic applications.70 We and
others have suggested that targeting the distal site interaction of BoNT inhibitors may
lead to inhibitors with reduced toxicity.35,74 Regardless of the approach, the development
of potent but low toxicity BoNT LC protease inhibitors could be a critical step in
rescuing nerve activity after toxin internalization.

1.4.1.1

Botulinum Neurotoxin Type A Inhibitors

So far, BoNT/A has been the main focuses for many researchers owing to their potent
toxicity. The studies for screening natural products to identify small molecule inhibitors
have reported a series of 4-aminoquinolines that were originally distinguished to prolong
the time required for BoNT/A to block neuromuscular transmission.75 A high-throughput
FRET-based assay for the screening of compounds libraries has reported that arginine
hydroxamic acid could modestly inhibit BoNT/A with a Ki value of 60 µM.76 On the basis
of screening a library of hydroxamic acids, 4-chlorocinnamic hydroxamate with an IC50
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value of 15 µM has been considered as a promising lead compound for further
development. Furthermore, a 2,4-dichloro-subsituted compound displayed competitive
inhibition against BoNT/A with a Ki value of 0.3±0.01 µM.77 The use of recombinant
fluorescent substrate in high-throughput screening of natural product extracts resulted in
identification of both an aqueous extract from the green star coral Pachyclavularia tosana
and three extracts from the African deciduous tree Terminalia brownii as inhibitors
against BoNT/A.78 In addition, a pseudopeptide inhibitor mimic of the 7-residue
sequences (QRATKML) of 206-residue SNAP-25 has been reported as a specific
BoNT/A inhibitor, which is the most potent non-zinc-chelating, non-hydroxamate-based
antagonist with a Ki value of 41 nM.79 Furthermore, the microsphere-based highthroughput screening of an off-patent chemical library has reported ebselen as an in vitro
inhibitor for BoNT/A LC by using full-length substrate.74 In summary, varied inhibitors
have been found including natural products, synthesized organic compounds with
structure-activity relationships, and peptide analogues based on different in vitro assay
methods. These studies have provided a strong framework to discover new BoNT/A
inhibitors as therapeutic agents. However, effective inhibitors that specifically target the
distal site interaction have not been discovered as of yet.

1.4.1.2

Botulinum Neurotoxin Type F Inhibitors

Among zinc metalloproteases, BoNT/F is unique with respect to its requirement of
inhibitor-binding groups on the N-terminal side of the substrate. The substrate analogues
introducing zinc-binding moiety (the sulfhydryl group), which is near the scissile bond in
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peptide 37-75, would inhibit BoNT/F protease activity.80,81,98 A series of peptide
analogues with a C-terminal Q58D-C mutations show effective inhibition against BoNT/F
with Ki values in nanomolar range.82 For instance, the substrate-based inhibitors inh1 and
inh2 consisted of VAMP residues 22-58 and 27-58 with Q58 replaced by D-cysteine
showed Ki values of 1.0 nM and 1.9 nM, respectively.82 In addition, several naturally
lectins containing sialic acid have been reported as effective inhibitors with a Ki value
around 100 nM in preventing BoNT/F from binding to the presynaptic terminal.83
However, very few BoNT/F inhibitors have been reported. Even though zinc chelators
are common inhibitors against BoNT/F, they are relatively inefficient in blocking the
activities of BoNT/F. As well, small molecule zinc chelators could have undesirable side
effects since they might inhibit other zinc-dependent proteases, with similar zinc binding
sites.84 At present, the development of substrate analogues with mutations of residues has
been the main focus of inhibitor studies. High-throughput screening of a library of
chemical compounds has also been used to identify potential inhibitors for BoNT/F, but
few compounds were identified as specific inhibitors. To discover small molecule
inhibitors for BoNT/F, the more compounds would be referred and screened based on
different high-throughput methods and chemical libraries. Again, inhibitors that target
the interaction between the VAMP distal sites and BoNT/F LC would potentially reduce
inhibitor toxicity.
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1.4.2

Anthrax Lethal Factor Inhibitors

Since the protease activity of lethal factor leads to the anthrax toxicity, inhibitors of LF
are currently being sought as effective therapeutics for the treatment of anthrax. Many
peptide substrate analogues and small molecule compounds have been reported as LF
inhibitors. The hydroxylamine derivative of peptide substrate, In-2-LF, has been found
with a Ki value of 1 nM, which is the most potent inhibitor identified to date.85 A series of
compounds containing N-oleoyldopamine and their analogues have been demonstrated to
be uncompetitive inhibitors of LF, owing to the presence of the oleic acid moiety and
double bond.86 Recently, Karginov et al have reported that some derivatives of βcyclodextrin inhibit LF action by blocking the transmembrane pore formed by PA
subunit.87 A systematically generated series of hydrazones with IC50 values in the
micromolar range have been reported against LF activity based on different in vitro
assays.88 Additionally, a series of mono-, di-, and tri-guanidinylated derivatives of
neamine have been synthesized representing a novel scaffold for LF inhibitors.89
Currently, many other small molecule inhibitors have been identified via highthroughput screening methods. For instance, a fluorescence polarization (FP)-based highthroughput screening of a collection of 2,835 small molecules and natural product
extracts using a full-length MAPKK substrate was used to identify inhibitors targeting
protease distal sites as well as active sites.90 A yeast-hybrid-based high-throughput assay
has been reported depending on a site-specific cleavage of the chimeric yeast containing
an LF-substrate to screen about 6,500 represented scaffolds to identify specific
inhibitors.91 A high-throughput fluorescence-based assay has also been performed to
screen a library of 14,000 compounds leading to the identification of new scaffolds that
19
	
  

inhibit LF activity in the low micromolar range.92 In addition, a chemical library of
10,000 small molecule compounds has been evaluated by matrix-assisted laser-desorption
ionization (MALDI) time-of-flight (TOF) MS combined with self-assembled monolayers
(SAMs) for parallel screening experiments to identify a LF inhibitor with a Ki of 1.1
µM.93 The discovery of small molecule compounds may facilitate the development of
novel, safe and effective anthrax pharmaceutical agents. The identification of LF
inhibitory peptides would allow us to synthesize more peptide analogues that potentially
have increased potency.

1.5 Surface-based Protease Assays
The development of a method to study proteases and identify their inhibitors with high
sensitivity in a multiplexed manner is of great importance in diagnosis of proteaserelevant diseases.94,95,96,97 Over the past decade, many attempts have relied on affinitybased

methods

to

assay

proteases

including

liquid

chromatography,98

gel

electrophoresis,99 or immunoassay.100,101 But many of them have a limitation for a
multiplexed assay or high-throughput screening. Afterwards, Forster (or fluorescence)
resonance energy transfer (FRET) has been employed for protease assays where two
fluorophores (energy donor and acceptor) are typically attached to the ends of the
substrates with a distance of less than 10 nm.102,103,104,105 Even though the FRET
technique has been widely used in solution assays, they are difficult to perform as
multiplexed assays for more than one protease simultaneously. More recently, quantum
dots (QDs) have been more attractive for use in protease assays, because they have more
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desirable photophysical properties than organic dyes including high quantum yield, less
photobleaching, and size-tunable photoluminescence with broad excitation and narrow
emission bandwidth.106,107 Due to these properties, QDs can serve as excellent probes for
a multiplexed and high-throughput protease assay with high sensitivity. Usually, the QDbased FRET assays use peptide substrates, which are smaller than full-length substrates
and don’t contain distant sites for protease binding that are present in full-length
substrates. What is needed is a multiplexable assay that can use full-length substrates.
This enables the use of multiple substrates that also include the necessary distal binding
elements.
The ability to study multiple proteases in a single assay format has many advantages
over single-target systems, that contains high-throughput screening, low consumption of
reagents and samples, protease selectivity and specificity. The need to measure the
activities of multiple proteases simultaneously using full-length substrates has resulted in
the invention of the multiplexed microsphere/nanosphere based protease assays.74,108 The
streptavidin-biotin system has been widely used to immobilize the substrate on surfaces
due to the strong non-covalent interaction between each other. In my research, I have
used this system to immobilize the protease substrates on microspheres or nanospheres
for protease activity measurement.

1.6 High-throughput Flow Cytometry for Drug Discovery
High-throughput screening is a critical step in the drug discovery process for the
pharmaceutical industry. Flow cytometry can perform homogeneous analysis of
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molecular assemblies or ligand binding by resolving the free vs. surface-bound
fluorescence molecules, when the single particle passes through a laser beam.109 This
property makes it simple to measure time-dependent fluorescence loss by determine the
original fluorescence intensity on the microspheres and the remaining fluorescence on
microspheres after protease cleavage without requirement of a wash step to remove
cleaved fluorophore.74 In addition, flow cytometry enables the simultaneous quantitative
analysis of a multiplex bead-based suspension array as the beads are color coded with
varying intensities of fluorescence to produce a series of bead sets.110 The microsphere
based high-throughput flow cytometry assay is a promising approach with several
advantages including: low substrate costs, small reaction volumes, homogenous assay
format, and use of full-length substrates to detect all pertinent interactions; however, it
has limitations in collection of traditional kinetic data. In my dissertation, I have
developed 1536-well plate-based high-throughput screening approach for evaluating a
library of about 350,000 compounds against three proteases simultaneously. Several
compounds have been identified to be potential inhibitors for specific proteases with Ki
values in the low micromolar or nanomolar range.

22
	
  

Chapter 2
Goals and Overview of This Study
The goal of this work is to develop a surface-based protease assay that enables the use
of full-length protease substrates, multiplexed assays, and most importantly, is highthroughput. These technical advances have also provided new insights into protease
kinetics and drug discovery.
In Chapter 3, we describe development of a four-plex microsphere based protease
assay. In this assay, three of the microsphere populations bear a unique fluorescent
protease substrate that is specific for a toxin protease and the fourth bears a negative
control substrate. Specific protease cleavage is reported via the loss of fluorescence from
a specific microsphere set. The fluorescent substrates containing the cleavage sites are
designed with a biotinylation tag at N-terminal and a GFP domain at C-terminal for three
proteases (LF, BoNT/A&F LCs) that can associate with streptavidin-coated microspheres.
When used in combination with high throughput flow cytometry, I demonstrated its use
to simultaneously screen the 1280 compound Prestwick library for inhibitory compounds.
This screen discovered a new inhibitory compound (riboflavin) that is specific for Lethal
Factor. Microsphere and FRET peptide-based dose response assays indicated that the IC50
values of riboflavin against Lethal factor were 15 µM and 17.4 µM, respectively. It also
confirmed the discovery of ebselen, which is a BoNT/A inhibitor that was previously
discovered using a BoNT/A specific screen.74
In order to identify additional efficient inhibitors, we then performed high-throughput
screening for a chemical library of 350,000 compounds using 1536-well plates and
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implemented on the HyperCyt® flow cytometry system, that could screen thousands of
compounds per day for protease inhibition. The hits were further characterized by
measuring IC50 values via microsphere-based, FRET peptide and FRET full-length
solution based protease assays. This screening led to the identification of 13 compounds
that inhibited the activities of LF, BoNT/A & F in the low micromolar range. To
understand the structure-activity relationships of these compounds, about 60 chemical
compounds with structure-activity relationships were tested in dose response reactions.
Then 11 compounds were distinguished with low IC50 values (< 20 µM) against three
proteases. These compounds were grouped in four scaffold types. Comparing the results
of full-length and peptide assays, three compounds with inhibition against BoNT/A LC
were shown to be potentially active at distal sites of SNAP-25 substrate. The relatively
low IC50 values, bioavailability, and potential distal interactions of these compounds
suggest that they may have great potential for medical applications and demonstrate the
value of simultaneous screening of multiple proteases using multiplex microsphere assays.
In Chapter 4, we built the FRET full-length substrate solution assay to determine the
kinetic constants of BoNT/A LC and inhibition mechanisms of some known inhibitors. In
this case, we used a biotinylation-tag and GFP-labeled protein substrates connected to
streptavidin-Cy3 conjugate as the cleavage targets for proteases in solution. Based on the
FRET (GFP to Cy3), the fluorescence intensity change was recorded on a fluorimeter or a
plate reader. Here, in addition to obtaining the key kinetic constants including kcat, Km and
kcat/Km of BoNT/A LC, the inhibition mechanisms of three specific compounds against
BoNT/A LC were determined.
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In Chapter 5, we would seek to understand the kinetic mechanism of these proteases
and further inhibition mechanisms of some inhibitor candidates based on surfaces. We
used the microsphere-based system to characterize the enzymatic reaction in terms of
three key kinetic parameters of BoNT/A LC (Km, kcat and kcat/Km) for surface-bound
substrate by flow cytometry. Due to the dead time limitation of typical flow cytometers,
we were limited in the ability to obtain the true protease cleavage rates. To understand
surface-based enzymatic reaction, it will be helpful to study the inhibition mechanisms
and determine the inhibition constants of some potential inhibitors. However, despite the
many advantages of microsphere-based assays used for screening, the surface area to
volume ratio of the microspheres limited us to sub-saturating concentrations of substrate
(the low nM).
Therefore, we developed a nanosphere-based protease assay platform using 380 nm
streptavidin-coated nanospheres. To demonstrate this approach, we implemented the
nanosphere-based protease assay using the toxin protease models to first demonstrate the
concept in Chapter 6. By trigerring flow cytometric analysis on the fluorescence on the
nanospheres, the substrate concentration was increased to the micromolar range and it
also confirmed the protease cleavage measurment for BoNT/A LC. The success of
nanosphere-based protease assay would provide a great platform to do both highthroughput screening for potential inhbitors and the kinetic study of these proteases.
Our future work discussed in Chapter 7 will focus on development of a nanospherebased, multiplexed protease assay for proteases such as matrix metalloproteases (MMPs)
that have reduced specificity and affinity for their substrates, which necessitates the use
of higher substrate concentrations to measure protease activities. Once developed, we
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will optimize the assay for use in high throughput flow cytometry screening and
demonstrate its effectiveness by screening the Prestwick library of chemical compounds
for potential MMP inhibitors. Additionally, we will study the enzyme kinetics of each
MMP to explore how MMPs recognize their substrates. The ability to screen several
proteases simultaneously will dramatically reduce screening labor and cost, immediately
provide information on specificity and mechanism of inhibition, and demonstrate an
approach to screening many members from a family of related proteases simultaneously.
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Chapter 3
Parallel Protease Assays Using Suspension Microsphere Arrays
3.1 Introduction
Anthrax lethal toxin (LT) and Botulinum neurotoxins (BoNTs) are critical to the
lethality of their host organisms, Bacillus anthracis and Clostridium botulinum,
respectively.58, 111 LT and BoNT are two-part toxins that have large protein subunit that
bonds to cells and an smaller subunit, which is an active protease component that cleaves
intracellular proteins to exert a toxic effect.112 As LT is a critical component of Anthrax,
a significant biothreat agent, and BoNT is a widespread pharmaceutical that is also most
toxic compound known, which makes it also a biothreat agent of grave concern, the
development of effective inhibitors for these toxins is of great interest.62,113
To this end, we are specifically interested in the protease subunits, which are lethal
factor (LF) of LT and the light chain (LC) of BoNT. Both of these proteases are zincdependent metalloproteases that target specific host proteins and are required for the
toxicity of the host organism or toxin, which makes them attractive targets for inhibitor
discovery.54,114 LF cleaves mitogen-activated protein kinase kinases (MAPKK) within the
N-terminal proline-rich region to disrupt protein interaction site for assembling signaling
complexes, leading to the death of host.58 Botulinum neurotoxins (BoNTs) family
consists of seven antigenically different botulinum neurotoxins (abbreviated BoNT/X LC
where the X is the type) serotypes, A-G, with serotype A, B, E and F responsible for most
natural human intoxications.115 Each of BoNT LC serotype is also a zinc-dependent
metalloprotease that cleaves a protein element of the SNARE (soluble N-ethylmaleimide27
	
  

sensitive fusion attachment protein receptor) complex found within the neurotransmitter
pathway, which leads to paralysis and death.116,117 Specifically, BoNT/A, C, & E LCs
cleave the synaptosomal-associated protein of 25 kDa (SNAP-25), while BoNT/B, D, F
& G LCs cleave vesicle-associated membrane protein (VAMP-2 also called
synaptobrevin), and BoNT/C LC also cleaves syntaxin.118,119
The detailed knowledge of these proteolytic pathways has led to many efforts,
including both rational inhibitor design and high throughput screening approaches, to
identify or synthesize potent and effective inhibitors for these critical proteases. These
efforts have developed few effective inhibitors leads and there are no effective
pharmaceuticals currently available for either the treatment of the late stage Anthrax
infection or BoNT intoxication.120
Rational design efforts have resulted in the development of peptide based inhibitors of
LF that include In-2-LF with a Ki of 1 nM,85 which is a peptide hydroxamate designed
on the basis of the N-terminal sequence of its MAPKK substrates. Many researchers have
designed small molecule inhibitors of LF that are weak hydroxmates (IC50s > 100 µM)
and chelating agents such as EDTA and ortho-phenanthroline.121 Additionally, a series of
competitive inhibitors against BoNT type A protease activity were reported recently,
which were synthesized by basing the inhibitor on the peptide structure from the cleavage
site within SNAP-25, with the Ki values higher than 300 nM.71 On the other hand,
substrate-analogue inhibitors of BoNT type F exhibited strong inhibition with Ki values
of nanomolar range.82 Hydroxamate inhibitors of proteases mimic the substrate in its
bound form or in the transition state form,122 this theory provides a structural basis for the
rational design of LF and BoNTs inhibitors with improved activates.
28
	
  

There has also been extensive work towards the development of high-throughput
protease assays.92,123 These include FRET assays124, enzyme-linked immunosorbent assay
(ELISA)125, and solid-phase assay.126 Of particular interest here are the microspherebased assays that use immobilized protease substrates on surfaces.69 An advantage of
surface based assays is the ability to use full-length substrates that include all elements
required for tight interactions between the protease and its substrate. This is of particular
importance for the development of assays for all strains of BoNT LC and LF, as these
proteases have extensive interactions at substrate sites distant from the cleavage site that
are require for optimal activity. Therefore, it is highly desirable to use full-length
substrates for BoNT LC and LF protease assays. Moreover, such assays may offer a
method to discover inhibitory compounds that do not target the highly conserved zinc
metalloprotease active site, which may lead to compounds with limited cross-reactivity
with cellular proteases such as matrix metalloproteases.74 Such an approach may lead to
metalloprotease inhibitors with much reduce toxicity, which has been problematic for
such compounds in the past.92
Due to the emergence of high-throughput flow cytometry, microsphere-based protease
assays have become effective methods to screen for protease inhibitory compounds.108
This approach has been used to screen individual proteases against relatively small
libraries of a about 1000 compounds or less.74,127.
Here, we have extended the strategy used to screen BoNT/A LC against the Prestwick
library of 1280 off-patent compounds using 384-well plated analyzed on the HyperCyt®
high-throughput flow cytometer.74 This approach uses a fusion protein that has a fulllength protease substrate between a biotinylation domain and a GFP domain. The
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biotinylation domain enable specific attachment of the protein to the surface of a
streptavidin coated microsphere. Proteolytic cleavage results in loss of GFP derived
fluorescence on the microspheres, which is monitored via flow cytometry.
In this study, we created a multiplex microsphere assays that can assay three proteases
simultaneously and demonstrated that we can use this assay to screen both the Prestwick
library and a large chemical library of 350,000 compounds. This work was implemented
using a cluster high-throughput flow cytometry system that can screen a 1536-well plate
in 12 minutes.128 These screens identified several lead compounds. We performed
secondary screening using FRET peptide assays and a newly developed FRET protein
assay. Both microsphere-based and FRET assays were implemented for dose response
measurement of compounds against LF, BoNT/A & F LCs, respectively. We also use
comparison of inhibitor activity on full-length substrate vs. peptide substrates to evaluate
for compounds that may specifically disrupt protease activity at sites distant from the
active site of the protease. This study has developed a method to screen three proteases
simultaneously against large chemical libraries, demonstrated that full-length substrates
can be used to discover distal site inhibitors, has discovered several new inhibitors for
BoNT/A & F LC and LF proteases.

3.2 Materials and Methods
3.2.1 Materials
DNA oligonucleotide primers were synthesized by IDT (Coralville, IA) and Operon
(Huntsville, AL). Terrific broth (TB) was purchased from Fisher scientific (Pittsburg,
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PA). SoftLinkTM avidin resin was obtained from Promega Corporation (Madison, WI).
Streptavidin-coated microspheres were obtained from Spherotech Corporation (Lake
Forest, IL). BoNT/A & F LCs and MAPKKide, SNAPtide FRET peptide were obtained
from List Biological Laboratories (Campbell, CA). Dithiothreitol (DDT), Isopropyl-β-Dthiogalactopyranoside (IPTG), Tris base, Tween 20, Bovine serum albumin (BSA),
Hepes hemisodium salt, Sodium chloride, Phosphate-buffered saline (PBS), Carbenicillin,
Chloramphenicol, Biotin, were purchased from Sigma-Aldrich corporation (St. Louis,
MO). The 384 and 1536-well plates were obtained from ISC BioExpress (Kaysville, UT).

3.2.2 Preparation of Biotinylated Substrate Plasmids
With enhanced green fluorescent protein (EGFP) cloned at the C terminus of the open
reading frame as described previously,69 protease substrate plasmids were designed based
on the Promega (Madison, WI) Pinpoint biotinylation tag vectors.69 The plasmids LF-15
GFP and SNAP-25 GFP were created as described previously.74 The VAMP-2 green
fluorescent protein (GFP) plasmid was created by first restricting the Factor Xa substrate
plasmid, also known as PinPiont GFP originally available from Promega (Madison, WI)
with (SacI and BamHI)69 and ligation of a VAMP-2 polymerase chain reaction (PCR)
product. To create the VAMP-2 substrate, we obtained the VAMP-2 sequence
(msataatvpp aapageggpp apppnltsnr rlqqtqaqvd evvdimrvnv dkvlerdqkl selddradal
qagasqfets aaklkrkyww knlkmmiilg vicaiiliii ivyfss) synthesized by Integrated DNA
Technologies (Coralville, IA). To move the synthetic construct into an expression
plasmid we use PCR to amplify the VAMP-2 from amino acid 1-96. The VAMP-2 PCR
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primers

were

5’-ATCTATGAGCTCATGTCTGCTACCGCT-3’

and

5’-

ATCCTAGGATCCTAGAAGTGCTGAAGTAAA-3’. The VAMP-2 DNA sequence was
denatured at 96 °C for 5 min, then the PCR procedure using AccuPrime™ Pfx DNA
polymerase that was performed with 39 amplification cycles as follows: 1) 96 °C for 30 s,
2) 60 °C for 30 s, 3) 72 °C for 45 s, then the product was extended at 72 °C for 10 min.
Finally, the reaction was maintained at 4 °C and the product was stored at -20 °C until
use. Then the PCR product was digested with SacI and BamHI, and cloned into the
PinPoint GFP plasmid between the same two sites.69 This effectively removed the Factor
Xa specific cleavage sequence and replaced it with VAMP-2 (1-96) sequence. This
VAMP-2 sequence was between the amino terminal biotinylation tag and the carboxy
terminal EGFP domain. This VAMP-2 (1-96) plasmid ligations were transformed into
calcium competent SCS1 Escherichia Coli.129 Minipreps were done with a Qiagen
(Valencia, CA) QIAprep miniprep kit (25) and were sequenced to confirm that the
VAMP-2 sequence was correct. For expression, the plasmids of interest were transformed
into calcium competent BL21 (DE3) pLysS competent E. coli cells from Novagen
(Madison, WI).

3.2.3 Expression and Purification of Biotinylated Protease Substrates
The expression and purification of all four biotinylated protease substrates were
performed essentially as described in our previous work.69 Briefly, a single colony
containing the respective plasmid for one of the four protease substrates was picked from
a LB plate and grown overnight in 3 mL of TB media containing 50 µg/mL carbenicillin
and 34 µg/mL chloramphenicol. Then the transformed cells were transferred to 250 mL
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of TB media with 50 µg/mL carbenicillin, 34 µg/mL chloramphenicol, 40 µM biotin and
grown at 37°C until OD600 reached 0.6-0.8. Then, cultures were induced by 100 µM
IPTG and grow overnight at 30°C. The cultured cells were harvested by centrifugation at
3500 rpm on a Beckman Avanti J-301 centrifuge for 30 min at 4°C and washed by water
twice to remove the biotin. The bacteria were resuspended in 40 mL of lysis buffer
(PBS+1mM DTT) followed by sonication. The suspended cells were sonicated in an ice
bath for 15 min and centrifuged at 14,800 rpm on a Beckman Coulter Allegra™ 64R
centrifuge using rotor FO685 for another 30 min at 4°C. The clear supernatant was
loaded onto a 5 mL SoftLinkTM soft release avidin resin from Promega (Madison, WI) at
a flow rate of 1 mL/min at 4°C. The PBS buffer with 5 mM biotin was used for eluting
the protein from the column. Following, the eluted sample was dialyzed with protease
buffer (50 mM HEPES, 100 mM NaCl, pH 7.4) for three times at 4°C to remove the free
biotin. The purified protein was confirmed with sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) with 80% purity after a single step. The concentration
was determined by using A280 spectroscopic measurement and the calculated extinction
coefficients.130

3.2.4 Prestwick Library Screening
Each of the four different GFP containing protease substrates were attached to a
specific population of Spherotech (Lake Forest, IL) streptavidin-coated pink particle kit
(SVFA-2558-6K) microspheres with different fluorescence intensities. The Factor Xa
substrate pinpoint GFP was incubated with the P.05 microspheres and used as a negative
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control. VAMP-2 GFP was bound to P.01 microspheres. SNAP-25 GFP and LF-15 GFP
were bound to P.09 and P.11 microspheres, respectively. To achieve binding, all the
microspheres were incubated with 100 nM of a specific protease substrate in a rotator for
an hour at room temperature. Then the bound microspheres were washed for three times
with protease buffer (50 mM HEPES, 100 mM NaCl, 1mg/mL BSA, 0.025% Tween-20,
pH 7.4) and centrifuged for one minute to remove the residual unbound protein. The
multiplex protease assay was carried out and measured by flow cytometry. All the bound
microspheres were mixed together in protease buffer (50 mM HEPES, 100 mM NaCl,
1mg/mL BSA, 0.025% Tween-20, pH 7.4). Then, four 384-well plates were used to set
up the reaction of 1280 compounds from the Prestwick chemical library. Wells 1 and 24
with only substrates from each row were used as positive controls. Wells 2 and 23 with
substrates and proteases from each row were used as negative controls. Other wells on
the plate were the samples with compounds and protease mixture. The assay plates were
incubated at room temperature for 2 hours on a plate rotator to keep beads in suspension.
All the plates were set up and sampled twice on the HyperCyt® high-throughput
screening system so as to get reliable assay results. Data were analyzed using HyperView
software.131 When analyzing the data, the Z’ factor was calculated for each microsphere
set by using the average mean and standard deviation values for wells containing no
protease as a positive control and wells without test compound as a negative control as
described in our previous work.74 Percent inhibition for each compound was calculated
by the following formula, 100% × [(averaged median well fluorescence – negative
control average median fluorescence)/ (positive control average median fluorescence –
negative control average median fluorescence)].
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3.2.5 Screen of 350,000 Compounds
In order to identify more efficient inhibitors against the proteases (LF, BoNT/A & F
LCs), the 1536-well plates were used to set up the reactions for screening of 350,000
compounds from NIH chemical library. Wells 45 and 46 from each row were used as
positive controls with substrates only and negative controls containing substrate and
proteases, respectively. Wells 1, 2, 3 and 4 from each row were added with protease
buffer alone to wash the probes. Other wells on the plate were the samples containing
mixtures of compounds and protease. The assay plates were incubated at room
temperature overnight on a plate rotator to keep beads in suspension. In this way, the time
points would supply the maximum protease cleavage of substrates and the ability to
screen plates sequentially. All the plates were set up and sampled on the HyperCyt® highthroughput screening system so as to get the reliable assay results. Data were analyzed as
described previously for Prestwick library.

3.2.6 Dose Response Measurement on Microspheres
The compounds with high inhibition efficiency (>30%) in HTS were advanced to the
confirmation testing with the same compound concentration used in HTS. The
concentration range of the compounds was from 10 nM to 50 µM. Percent inhibition was
calculated by the formula: 100%× [(test sample fluorescence value-negative control
fluorescence value)/(positive control fluorescence value-negative control fluorescence
value)]. To test the inhibition of riboflavin against BoNT/A LC, a duplex protease assay
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was set up and measured by an Accuri C6 flow cytometer. The samples were tested every
30 min within two hours.

3.2.7 FRET Solution Dose Response
The FRET peptides including MAPKKide for LF and SNAPtide for BoNT/A LC from
List Biological Laboratories were used as substrates to test the inhibition ability of the
potential inhibitors by a fluorimeter (QuantaMaster™ 50 spectrofluorometer, Photon
Technology International) with an excitation wavelength of 490 nm and emission
wavelength of 523 nm. The concentrations of the compounds were varied from 10 nM to
50 µM. The positive control sample was prepared with FRET substrate with mixing with
the proteases, whereas the negative control sample was the substrates only. The test
sample was the mixture of substrates, proteases and selected compounds. Percent
inhibition was calculated by the formula: 100%×[(slope of test sample - slope of negative
control sample)/(slope of positive control sample – slope of negative control sample)].
The FRET full-length substrate for BoNT/A LC was used to test the inhibition ability
of the potential inhibitors by a fluorimeter (QuantaMaster™ 50 spectrofluorometer,
Photon Technology International) with an excitation wavelength of 450 nm and emission
wavelength of 507 nm. The concentrations of the compounds were varied from 10 nM to
50 µM. The positive control sample was prepared with FRET substrate and proteases,
whereas the negative control sample was the substrates only. The test sample was the
mixture of the substrates, proteases and test compounds. Percent inhibition was
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calculated by the formula: 100%×[(slope of test sample - slope of negative control
sample)/(slope of positive control sample – slope of negative control sample)].

3.3 Results and discussion
3.3.1 Development of Multiplexed Protease Assay
A multiplex microsphere-based assay can allow parallel evaluation of multiplex
proteases and identification of specific inhibitors against the corresponding proteases.
Here, we designed a few protease substrates that are fusion proteins containing a
biotinylation tag and GFP domain separated by the full-length protease substrates. We
used the streptavidin-coated fluorescent suspension microsphere arrays (SAM) where a
unique protease substrate was borne by each microsphere population. We developed a
multiplex substrate set containing four substrates (a SNAP-25 fusion protein, a VAMP-2
fusion protein, a fusion protein bearing a LF cleavage site, and a negative control
substrate) that have been engineered for use with three proteases, Clostridium botulinum
neurotoxin type A & F light chains and Bacillus anthracis lethal factor (BoNT/A & F
LCs and LF), simultaneously in HTS assays for discovery of small molecule inhibitors
(Figure 3.1A). Each protease substrate was attached to a set of fluorescent streptavidincoated microspheres via its biotinylation tag. The protease assay was incubated overnight
in order to obtain maximal protease cleavage. The protease activity is measured by
detecting the fluorescence loss from microspheres as shown in Figure 3.1B.
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Figure 3.1 A. 4-plex multiple protease assay. VAMP-2 (BoNT/ F substrate), SNAP-25
(BoNT/A substrate), LF-15 (LF substrate) attached to microspheres and control Pinpoint
GFP (Factor Xa substrate). The colored circle stands for different microspheres, the blue
crescent for streptavidin, the brown oval for biotinylation tag, the colored cylinders for
different protease substrates. Cleavage sites are red, distal sites are brown & orange. B.
Protease cleavage activities were measured by loss of fluorescence from microspheres via
flow cytometry after adding three proteases simultaneously.
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The microsphere population was analyzed via flow cytometry and gated based side
scatter vs. forward scatter (Figure 3.2A). The different microsphere populations were
distinguished by gating on differences in fluorescence intensities as shown in a bivariate
dot plot of side scatter vs. red fluorescence (Figure 3.2B). The multiplex protease assay
was executed by adding three proteases (1 nM BoNT/A LC, 75 nM BoNT/F LC and 300
nM LF) as a single mixture simultaneously. The results indicated that all the proteases
could recognize and cleave their specific substrates (Figure 3.2C). In comparison with
anthrax lethal factor, BoNT/A & F LCs exhibited higher proteolytic cleavage activity.
This may be due to the presence of exosites on the VAMP-2 and SNAP-25 substrates,
which are lacking from the LF-15 substrate as it is simply a 15 amino acid sequence
derived from a consensus cleavage site.35,132 Regardless, this method demonstrated
feasibility of measuring the activity of several different proteases in the same sample.
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Figure 3.2 A. Bead populations were gated in the dot plot. B. Each bead population was
separated by FL4 (Red) channel, One type of beads are used as blank. Each other type
bears different GFP substrate. C. The time-course cleavage results of three multiple
protease assay. Substrate types are as follows: control ppGFP, VAMP-2 GFP, LF-15 GFP
and SNAP-25 GFP.
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3.3.2 Primary Screening of Chemical Libraries
In the Prestwick library, about 1280 off-patent drugs and bioavailable compounds were
screened in four 384-well plates twice. The activities of proteases led to the loss of
fluorescence of substrate proteins resulting about 80% reduction of fluorescent signal. All
Z’ values were calculated for each substrate based on the time endpoint fluorescence
intensity of positive and negative control wells, respectively. When the Z’ value was
lower than 0.4 or the event number was lower than 50, the data would not be analyzed or
used. The average Z’ value for each substrate was as following: 0.81 for SNAP-25 GFP,
0.86 for VAMP-2 GFP and 0.7 for LF-15 GFP, respectively (Figure 3.3). In the primary
screen, two compounds were discovered to inhibit cleavage by more than 30% inhibition.
Riboflavin showed about 80% inhibition against LF and 40% inhibition against BoNT/A
LC respectively. Tolazamide showed about 35% inhibition against LF.
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Figure 3.3 High-throughput screening for small molecule inhibitors against proteases. (A)
Plot of high-throughput screening data of positive control substrate Pinpoint GFP. All the
data were collected in the FL1-A green fluorescence channel. (B) Plot of high–
throughput screening data of BoNT/A LC. Arrow denotes the positive control well (PC)
and the inhibitor well Hit). (C) High–throughput screening data of BoNT/F LC. Arrow
denotes the positive control well (PC) and the inhibitor well (Hit). (D) High–throughput
screening data of LF. Arrow denotes the positive control well (PC) and the inhibitor well
(Hit). All the reactions were performed in protease buffer (pH=7.4) and at room
temperature. Each panel represents fluorescence intensity data from all wells of a 384well plate that were gated on the bead set bearing the indicated protease substrate.
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In addition, about 350,000 chemical compounds were screened in around two hundred
1536-well plates. All Z’ values were calculated for each substrate based on the time
endpoint fluorescence intensity of positive and negative control wells, respectively. The
average Z’ values for each substrate were above 0.7 showing excellent HTS quality.
Hundreds of compounds with inhibition >50% were advanced into confirmatory
screening. There were 610 compounds for BoNT/A LC, 780 compounds for BoNT/F LC
and 423 compounds for LF, respectively. In the confirmatory screening, all these
compounds were tested in triplicate for their effect against three proteases. Confirmed
results were reviewed, 19 compounds that inhibited the activity of BoNT/A LC, 11
compounds that inhibited the activity of BoNT/F LC, and 10 compounds that inhibited
activity of LF. These compounds were selected into follow-up dose response assays to
determine the IC50 values.
From the dose response reactions above, 13 compounds were selected with great IC50
values (< 20 µM) as showing in Table 3.1. In these compounds, some of them displayed
specific inhibition against BoNT/A LC including CID 4464849, CID 4293343 and CID
256073. CID 3626685 and CID 3095057 inhibited the activity of BoNT/F LC. Four
compounds showing inhibition against LF are CID 3335282, CID 4472168, CID
51360688 and CID 51361178. Meanwhile, CID 392789 inhibited the activities of
BoNT/A & F LCs. Only CID 12006136 inhibited the activities of BoNT/A & F LCs and
LF. This HTS assay exhibited robust, rapid and reproductive advantages, which also
demonstrated significant selectivity of the compounds.
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Table 3.1 IC50 values of each inhibitor for microsphere-based assay.
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3.3.3 Riboflavin Can Inhibit Lethal Factor Activity
Because of the excellent inhibition activity of riboflavin (Figure 3.4A) found in HTS
of the Prestwick library, a detailed dose response assessment was carried out afterwards.
The results showed that riboflavin inhibited the activity of lethal factor at the
concentration of 20 µM (Figure 3.4B), and the IC50 value of riboflavin against LF was
about 15 µM. However, tolazamide could not inhibit lethal factor at even higher
concentrations (data not shown). In order to confirm the inhibitory activity of riboflavin,
MAPKKide peptide was used in the FRET solution assay. The peptide substrate was
synthesized with a fluorophore FITC (energy donor) linked at the C-terminal end and
another fluorophore DABCYL (energy acceptor) attached to the N-terminal end. When
the peptide bond of the substrate was cleaved, the FRET was interrupted and the
fluorescence signal from FITC was increased. It is a sensible strategy to test the
inhibition ability of riboflavin against LF by measuring the cleavage rate of LF. The
fitting results demonstrated that riboflavin inhibited the activity of LF at the IC50 value of
17.4 µM (Figure 3.4C), which was very close to that obtained with the microsphere-base
method (15 µM).
Based on these results, it is reasonable to infer that the inhibition mediated by
riboflavin represents a complex mechanism. Because riboflavin is an amphipathic
molecule that allows a large variety of different interactions with the enzyme itself and
the substrate,133 Riboflavin may interfere with the interaction of LF-substrate complex. It
is necessary to note that riboflavin is essential for many important enzymatic reactions in
vivo. Furthermore, riboflavin has been used in several clinical and therapeutic situations
because of its importance in the maintenance of many human tissues. In this assay, we
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found that riboflavin inhibited the activity of lethal factor, so it may have utility in the
development of lead compounds that may result in therapeutics for late stage Anthrax
infections.
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Figure 3.4 Dose-response inhibition curves for the compound riboflavin against 400 nM
lethal factor. All the reactions were performed in protease buffer (pH=7.4) and at room
temperature. All the data were fitted according to the equation: % inhibition = Bottom +
(Top - Bottom)/(1+ 10((Log(IC50)-X)

× (Hill coefficient))

). (A) Structure of riboflavin. (B)

Microsphere-based assay using biotinylated tag lethal factor substrate green fluorescence
protein. The fit resulted in an estimate of the IC50 to be 15 µM and the fit gave an R2 of
0.962. (C) Inhibition of riboflavin against lethal factor was tested by MAPKKide peptide
substrate. The data were collected and calculated for 10 min after protease addition. The
result showed the IC50 to be 17.4 µM and R2 of 0.893.
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The HTS results showed that riboflavin inhibited BoNT/A LC activity around 40%.
The detailed dose response assay was also applied for riboflavin against BoNT/A LC
using the microsphere-based method. After one-hour incubation, the percent inhibition
mediated by riboflavin was about 40% at a concentration 25 µM. Even at higher
concentrations (100 µM, 500 µM), no greater inhibition was detected (Figure 3.5). This
result was consistent with HyperCyt® screening results. Over two-hour incubation, the
fluorescence intensity was measured for each sample every 30 minutes. Maximum
inhibition of BoNT/A LC cleavage of about 40% was observed at 30 min at riboflavin
concentrations of 25 µM and 100 µM, with no additional inhibition at long time (Figure
3.5). Here, we also used ebselen as a contrast, which has been identified as an inhibitor
against BoNT/A LC with the IC50 value of 5 µM.74 In this assay, 10 µM ebselen was
added for incubation of two hours, the results showed that ebselen inhibited the activity
of BoNT/A LC with about 100% consistent the previous report.
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Figure 3.5 Microsphere-based assay of riboflavin against the BoNT/A LC substrate
SNAP-25 GFP by measuring loss of green fluorescence. 5 nM of BoNT/A LC was added
into the microspheres containing a green fluorescent protein labeled substrate. The
fluorescence intensity was measured every 30 min by flow cytometry. All the reactions
were performed in protease buffer (pH=7.4) and at room temperature.
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3.3.4 Tests of Structure-activity Related Compounds
To find more potent compounds, we tested about 60 structurally related compounds
that were synthesized based on the structures of the lead compounds. This synthesis
occurred at Vanderbilt University. Using the microsphere-based assay, 11 compounds
were identified with inhibition against the three proteases. The dose response curve of
each compound was diagramed to determine the IC50 value (Figure 3.6). Of these dose
response curves, all were well behaved with the exception of compounds 2865835 and
2827281. These curves were clearly affected by spurious values at high concentration of
compound, which is believed to have occurred due to the fluorescence for these
compounds. When the spurious values were removed for compounds 2865835 and
2827281, the fits provided improved estimates of IC50 values (Figure 3.7).
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Figure 3.6 Dose response curves of 11 compounds with structure-activity relationships.
The concentration range of compounds was from 10 nM to 100 µM. Black circle is for
BoNT/A LC. Blue square is for BoNT/F LC. Red triangle is for LF.
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Figure 3.7 Dose response curves of compounds 2865835 and 2827281 with removed
spurious values. Black circle is for BoNT/A LC. Blue square is for BoNT/F LC. Red
triangle is for LF.
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Specifically, all the compounds inhibited the activity of BoNT/A LC with the IC50
values < 20 µM, and some of them displayed selectivity across proteases (Table 3.2). For
instance, in scaffold A, all of the compounds inhibited the activities of all three proteases.
However, compound 5056211 provided an IC50 estimate >20 µM in the BoNT/F LC
assay. In scaffold B, CID 564008 showed strong inhibition against both BoNT/A & F,
but very weak inhibition of LF. This suggests that this compound may selectively inhibit
the activities of BoNT LC proteases. The discovery of such lead compounds through
comparison of a parallel assays using related enzymes is likely to be an efficient method
for discovery of highly specific protease inhibitors that can be extended to many other
protease families.
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Table 3.2 Summary of IC50 values for 11 compounds against proteases in microspherebased assay.	
  They are diagramed into four scaffolds based on the structures.
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3.3.5 Evaluation of Lead Compounds Against BoNT/A LC in Solution Assay
The IC50 values for the 11 componds were determined using a FRET peptide based
solution assay. This was done to distinguish lead compounds that were only active in an
assay using a full-length substrate vs those that would inhibit regardless of the presence
of distal sites on the substrate. For this we focused on BoNT/A LC and used FRET
peptide assyas based on the SNAPtide fluorescent peptide developed by List
Laboratories.134 All 11 powder compounds have been tested here by 10-point titration
assays (Figure 3.8). The results of IC50 fits are in Table 3.3. Here, three compounds (CID
564008, CID 2214213 and CID 1299052) did not inhibit the activity of BoNT/A LC for
the FRET peptide substrate, but inhibited the activity of BoNT/A LC for the full-length
substrate in microsphere-based assays. This strongly suggested that these three
compounds were inhibiting BoNT/A LC activity by changing the ability of the full-length
substrate to bind to the protease. As tight binding is known to be mediated by the distal
sites of SNAP-25, it is reasonable to hypothesize that these compounds are targeting
these distal site interations, but additional confirmatory work is necessary to fully support
this conclusion.
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Figure 3.8 The dose reponses curves of the compounds that inhibited the acitivity of
BoNT/A LC in FRET peptide solution assay.
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Table 3.3 Comparition of IC50 values of 11 compounds for both microsphere-based and
FRET peptide assays against BoNT/A LC.
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One of the first confirmation steps to take is to evaluate whether the microsphere assay
that has a tethered substrate is providing different results due to the surface attachment of
the protease substrate. Though surface attachment enables simple use of full-length
substrates, they also limit the concentration of substrate in the reaction and require
enzyme saturating conditions (i.e. single turnover) to achieve maximal cleavage rates.69,
135

Therefore, a FRET assay that uses a full-length substrate was created as described in

Chapter 4. Though this assay has many uses, in this Chapter we will only consider it for
estimation of IC50 values of lead inhibitory compounds.
In summary, the full-length FRET substrate (flFRET) was constructed by incubating
the biotinylated SNAP-25 GFP in the presence of a 3:1 molar excess of Cy3 labeled
streptavidin (SA-Cy3). The binding of the SA-Cy3 to the SNAP-25 resulted in the
quenching of GFP when the flFRET was excited at 450 nm (to minimize direct excitation
of Cy3). Upon the addition of protease, the SNAP-25 is cleaved, which separates the GFP
from the SA-Cy3 and results in dequenching of GFP fluorescence, which is the indicator
of protease activity.124
In order to confirm the inhibitors, which were identified in both microsphere-based and
FRET peptide assays, we carried out the FRET full-length solution assay to determine the
IC50 values of the eleven compounds that have structural-activity relationships. Here, all
the compounds inhibited the activity of BoNT/A LC with the IC50 values lower than 20
µM using FRET full-length substrate. Additionally, three compounds including CID
564008, CID 2214213 and CID 1299052 were confirmed to inhibit BoNT/A LC activity
(Figure 3.9). The IC50 values of three inhibitors were 3.1 µM, 0.4 µM, and 0.6 µM,
respectively (Table 3.4). These results confirmed that these specific compounds might
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block the binding of substrate and enzyme at distal elements that inhibited the cleavage
activity of protease.

Figure 3.9 Dose response curves of three specific compounds that inhibited the activity of
BoNT/A LC in FRET full-length assay.
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Table 3.4. The IC50 values of the three specific inhibitors by using different substrates
and methods.
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3.4 Conclusion
In this study, we have designed a highly selective microsphere-based protease assay
and small molecule inhibitor selection system, which could be critical for the efficacy of
potential multiplex proteases and compounds assays. The improvement in highthroughput screening performance represents that this approach can be used to select
more protease inhibitors efficiently. Our multiplexed microsphere protease assay
combined with high throughput flow cytometry will be applicable to a broad range of
proteases due to its ability to rapidly discover inhibitors from large chemical libraries.
Here, we have identified several specific inhibitors for the proteases. This screen
discovered a new inhibitory agent (riboflavin) that was specific for Lethal Factor. The
major finding described here is the inhibitor (riboflavin) against LF, which is a
conventional compound and people can get it from daily diet. In addition, we have
identified several specific inhibitors with the IC50 values lower than 20 µM for BoNT/A
& F LCs and LF proteases. Some of these compounds displayed specific inhibition
against only one kind of the proteases that they may not be the inhibitor against all the
zinc-dependent metalloproteases. Additionally, a compound (CID 564008) specifically
inhibited the activities of BoNT/A & F LCs. These compounds may represent the BoNTs
inhibitors. These compounds (CID 564008, CID 2214213, and CID 1299052) were
shown to be active at sites distal from the active site. Compared the results with those
obtained from microsphere-based assay and FRET solution assay, the identification
specific inhibitors indicated the great importance of distal events in the interaction
between proteases and substrates. Blocking the binding of proteases and substrates at
exosites would play an important role in the inhibition of protease activity. The
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improvement in high-throughput screening performance represents that this approach can
be used to select more protease inhibitors efficiently. Our multiplexed microsphere
protease assay combined with high throughput flow cytometry will be applicable to a
broad range of proteases due to its ability to rapidly discover inhibitors from large
chemical libraries. The multiplexed microsphere-based protease assay for highthroughput screening has demonstrated a great ability to screen several proteases
simultaneously that dramatically reduces screening labor and cost, immediately provides
information on specificity of an inhibitor.
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Chapter 4
Kinetic Analysis of Botulinum Neurotoxin Type A Light Chain Using
FRET Full-length Substrate
4.1 Introduction
Assays of protease activity have been designed by combining substrates with
appropriate reporters, such as fluorescence and bioluminescence.136,137 Therefore, Forster
(or fluorescence) resonance energy transfer (FRET) has been widely used to assay the
protease where two fluorophores (energy donor and acceptor) are typically attached to the
ends of the substrate with a distance of less than 10 nm. FRET is a process in which
energy is transferred nonradiatively from an excited state donor to a proximal ground
state acceptor via resonant dipole-dipole interactions. When a protease substrate (peptide
or full-length) brings donor and the acceptor into close proximity, the activity of protease
gives rise to the change in FRET efficiency. The cleavage of the FRET substrate with a
protease disrupts the energy transfer and the ratio of donor and acceptor fluorescence
emission changes when both chromophores are fluorescent, or the fluorescent intensity
increases when the acceptor is a quencher.
In this work, we developed a FRET assay that uses a full-length SNAP-25 substrate
with a donor fluorophore (GFP) on one end of the full-length substrate and a paired
acceptor (Cy3-streptavidin) on the other end, attached to the substrate biotinylation tag.
This has the advantage that distal elements can be included in the substrate, the substrate
can be used in saturating conditions required for Michaelis-Menten kinetics, and is based
on the same substrate used in the microsphere assay.
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4.2 Materials and Methods
4.2.1 Materials
Tween-20, dithiothreitol (DDT), isopropyl-β-D-thiogalactopyranoside (IPTG), Bovine
Serum Albumin (BSA), Hepes Hemisodium Salt, Sodium Chloride, Phosphate-buffered
Saline (PBS) and Biotin were bought from Sigma-Aldrich Corporation (St. Louis, MO).
BoNT/A LC was bought from List Biological Laboratories (Campbell, CA). SoftLinkTM
streptavidin resin was obtained from Promega Corporation (Madison, WI). StreptavidinCy3 conjugate was bought from Invitrogen.

4.2.2 GFP Quenching by Cy3-Streptavidin
The concentration of CyTM3-Streptavidin Conjugate (ZyMAXTM Grade) from
Invitrogen was measured by A552 and A280 spectroscopic measurement (manufacturer
protocol) using Nanodrop 2000C spectrophotometer. The general excitation wavelength
of GFP is 488 nm, which could partially excite Cy3. Therefore we chose to use an
excitation wavelength of 450 nm to avoid the excitation of Cy3 because this wavelength
could only excite Cy3 with about 1%. To determine the biotinylated SNAP-25 GFP
quenching by Cy3, 25 nM SNAP-25 GFP was incubated with increasing amounts of Cy3streptavidin for 1 hour at room temperature in the protease buffer avoiding light, then the
ratio of SNAP-25 GFP quenching by Cy3-streptavidin was optimized by exciting the
sample at 450 nm in a PTI fluorimeter with slit lengths of 2 nm used with an emission
scan between 488 nm to 650 nm.
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4.2.3 FRET Solution Kinetic Assay
The real-time FRET based protease assays were employed to determine the kinetic
constants of BoNT/A LC cleavage activity. The substrate concentrations were varied
from 5 to 3000 nM with fixed 5 nM BoNT/A LC for the cleavage reaction. The
biotinylated SNAP-25 GFP was incubated with CyTM3-Streptavidin conjugate at the
molar ratio of 1:3. Then the sample was run for 1 minute in a PTI fluorimeter collecting
10 data point per second with slit sizes of 2 nm (the excitation wavelength was 450 nm
and emission wavelength was 507 nm). Then, 5 nM BoNT/A LC was added at the 60
second time point and the reaction was monitored for additional 10 min. Samples were
run in glass cuvettes with a stir bar providing continuous mixing. The concentration of
cleaved SNAP-25 GFP was calculated as follows:
[C ]cleaved =

F − FFRET
× [C ]GFP
FGFP − FFRET

Where, [C]cleaved is the concentration of cleaved SNAP-25 GFP; F is the fluorescence
intensity of each data point after adding 5 nM BoNT/A LC; FGFP is the average
fluorescence values of the free SNAP-25 GFP with the same concentration in the reaction;
FFRET is the average fluorescence values of FRET substrate without cleavage in the
reaction; [C]GFP is initial concentration of SNAP-25 GFP for each reaction. The data in
first 30 seconds after the cleavage were linearly fitted to determine initial rates of SNAP25 cleavage as the initial velocity of the reaction. All these values were then plotted
against different SNAP-25 GFP concentrations, and fitted to the Michaelis-Menten
equation with the nonlinear fitting curve.
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4.3 Results and Discussion
4.3.1 GFP Quenching by Cy3-Streptavidin
The full-length FRET substrate was constructed as shown in Figure 4.1A. The
biotinylated SNAP-25 GFP was linked to Cy3 labeled streptavidin via the SNAP-25
biotinylation tag. Due to the spectral overlap of GFP and Cy3, when GFP was excited at
450 nm (to minimize direct excitation of Cy3), this system demonstrated a concentration
dependent quenching of GFP fluorescence as increasing amounts of Cy3-streptavidin
were added to the system due to FRET, which occurred between the two fluorophores as
they were brought close together by the protease-sensitive linker (Figure 4.1B). This was
considered as an indicator of protease activity because SNAP-25 proteolysis disrupted the
energy tranfer process by separating the donor and acceptor units. The emission spectra
measurement indicated that the optimal molar ratio of SNAP-25 GFP and Cy3streptavidin was obtained for the best FRET substrate.
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Figure 4.1 A. Schematic of full length FRET solution assay. B. Cy3 streptavidin titration
onto 25 nM biotinylated SNAP-25 GFP. Excitation was done at 450 nm to avoid direct
excitation of Cy3 and emission spectra from 488 nm to 650 nm were collected at one data
point per nm.
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4.3.2 BoNT/A LC Cleavage of A Full-length SNAP-25 Substrate in Solution
At present, the FRET assay has been widely used due to its inherent sensitivity to the
molecular-scale rearrangement in donor-acceptor separation distance.138 To study the
cleavage of BoNT/A in a solution assay, a full-length FRET system was constructed by
biotinylated SNAP-25 GFP conjugated with Cy3 labeled streptavidin. Subsequently, this
FRET substrate was used to measure the enzymatic activity of BoNT/A LC. Proteolysis
of SNAP-25 provided an increase in GFP fluorescence at 507 nm as the cleavage activity
separated the two fluorophores. The first 60 seconds of fluorescence was recorded as
background, the protease cleavage was initiated by the addition of BoNT/A LC. The
cleavage rate increased in a concentration-dependent manner with the increasing of
FRET-substrate concentration (Figure 4.2A). To determine the initial velocities at each
substrate concentration, the increase in fluorescence as a function of time over the first 30
seconds was fitted to a line. The slopes of the lines provided the initial velocities, which
were plotted as a function of increasing substrate concentration and fitted to a hyperbolic
function to obtain the Vmax and Km values of 4.37 ± 0.29 nM/s and 0.87 ± 0.14 µM,
respectively (Figure 4.2B). kcat was calculated as 0.87 s-1 by dividing Vmax by the enzyme
concentration (5 nM) used in the assay because of  𝑉!"# = 𝑘!"# [𝐸]! .139 These values
provide a specificity constant (kcat/Km) of 1×106 M-1s-1.
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Figure 4.2 Cleavage analysis of BoNT/A LC based on FRET solution assay. A. Progress
curves for the cleavage reactions using 5 nM BoNT/A LC and different starting
concentrations of substrate, which are shown in the legend where the numbers indicate
substrate concentration in nM. B. The concentration-dependent initial rates versus
substrate (S) concentrations are fitted to a hyperbolic curve, Vmax[S]/(Km+[S]), to obtain
the kinetic constants Vmax and Km.
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Generally, the studies with BoNT/A LC and full-length substrates or at least 61-mer
fragment of SNAP-25 exhibited the constant kcat/Km values between 104 and 106 M-1s-1,
which were larger than the range of 102 to 103 M-1s-1 for BoNT/A LC and a 17-mer
SNAP-25 fragment.140 In addition, the values of Km and kcat associated with full-length
SNAP-25 were less than those associated with the 17-mer of SNAP-25 fragment.140
When compared to literature values of kcat determined on full-length substrate (2.4 and 17
s-1),141,142 the values in my work were smaller, but this was likely due to differences in
buffers, enzyme preparations, and these assays were performed at room temperature
rather than 37°C. It was also possible that the cleavage rate was reduced due to effects of
the biotinylation and GFP domains found in our SNAP-25 GFP substrate. A fluorigenic
assay using a 17-mer fragment of SNAP-25 resulted in values of Km, kcat and kcat/Km of
1.1±0.1 mM, 23±1 s-1 and 21×103 M-1s-1, repectively.143 These results also suggested a
probability that only a fraction of substrate-enzyme collisions were productive to form
product and the cleavage reaction appeared to be the limiting step. The kinetic analysis of
BoNT/A based on different substrates and methods have been widely studied because this
toxin-substrate combination may represent an optimal condition for selecting a standard
to evaluate the effectiveness of candidate inhibitors in in vitro assays.

4.3.3 Determination of The Cleavage Rate of A Small FRET Peptide
A 13-residue peptide based on the cleavage site of SNAPtide labeled on the N-terminus
with FITC and the C-terminus with DABCYL144 was used to measure cleavage rates.
When the initial velocities of these cleavage assays were plotted as a function of
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increasing FRET peptide concentration, they were clearly linear up to concentrations as
high as 10 µM (Figure 4.3). The slope of this line (when [S]<<Km) is indicative of a
specificity constant kcat/Km=1.12×104 M-1s-1.145,146 The use of higher substrate
concentrations in this assay was limited by the solubility of the FRET peptide, but even
so this analysis allowed us to put limits on the possible values of kcat and Km for the
FRET peptide substrate. As the concentration of BoNT/A LC used in this assay was 5 nM
and the plot indicates Vmax must be greater than ~0.6 nM/s, this allowed us to estimate kcat
as > 0.12 s-1. However, I have also measured the cleavage rates of a FRET peptide
(Figure 4.3) and the maximal rate determined (>0.12 s-1), which was of the same relative
order of magnitude as observed for our other assays. Additionally, as no saturation of
rates occurred at concentrations as high as 10 µM, the Km must be > 10 µM.
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Figure 4.3 FRET peptide cleavage assay was shown as velocity versus peptide
concentrations. The linear fitting curve was obtained to estimate kcat/Km (= 1.12×104 M-1s1

) when [S]<<Km.
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4.3.4 Inhibition Mechanism Determination of Specific Compounds Using Full-length
Substrate in Solution
In order to determine the inhibition mechanisms of the three specific compounds, 5
µM compounds were added into the samples before protease cleavage. All these
compounds showed competitive inhibition with Ki values of 1.8 µM, 3.6 µM and 2.7 µM
for CID 564008, CID2214213 and CID 1299052, respectively (Figure 4.4 A, B and C).
These results were consistent with the IC50 value determination based on both peptide
and full-length substrates assays. The results also illustrated that these compounds may
compete with enzyme binding to substrate at distal sites so that the blocked binding of
enzyme and substrate inhibited the activity of protease cleavage. The identification of
these compounds would provide a great platform to design more active structure-related
compounds as potential inhibitors against BoNT/A LC. This discovery is also promising
for clinical application of these compounds as beneficial medicines to treat many protease
related diseases.
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Figure 4.4 Inhibition determinations of three compounds. A. CID 564008 showed
competitive inhibition with a Ki value of 1.8 µM. B. CID 2214213 showed competitive
inhibition with a Ki value of 3.6 µM. C. CID 1299052 showed competitive inhibition
with a Ki value of 2.7 µM.
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4.4 Conclusion
We have successfully developed the FRET solution assay with full-length substrate to
determine the key kinetic constants of BoNT/A LC as well as the IC50 values of specific
inhibitors. Due to the FRET pairs of GFP and Cy3, we carried out the FRET assays for
BoNT/A LC to perform kinetic analysis and inhibitor identification. The identification of
specific inhibitors would originate the design of some compounds that share similar
structural characteristics with these inhibitors. The application of these compounds would
provide a promising interest for clinical treatment of the diseases caused by BoNT/A
toxin.
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Chapter 5
Kinetic Study of Botulinum Neurotoxin Type A Light Chain on
Microspheres by Flow Cytometry
5.1 Introduction
Multiplex microsphere assays have been developed for many enzymatic applications
including the measurement of DNA polymerase activity, exonuclease activity, and
protease activity.147,148,69 However, it is well recognized that, while microsphere and
surface based assays in general have the advantage of making single turnover assays
simple to perform, they do not permit substrate to be at saturating levels, which is
required for the evaluation of Michaelis-Menten kinetics.149 Nonetheless, to overcome
this limitation several efforts have led to new kinetic models that may enable direct
measurement of kinetic parameters, such as kcat and Km, when substrate is not
saturated.150,151 Of specific interest here is an approach developed by Gutierrez et al, that
treats heterogeneous assays as enzyme quasi-saturable systems (EQSS).135 They have
developed a quantitative model of general kinetic behavior in EQSS that enables
determination of kcat, Km and Ki values. This model is mathematically consistent and has
been used to quantify HIV protease activity on a flat surface.152 If this approach is valid it
has significant value for the many surface based high-throughput screening (HTS) efforts
for proteases and other enzymes.74,153
The need for such models is particularly important for HTS for inhibitors of the
botulinum neurotoxin type A light chain protease (BoNT/A LC).72 This protease is one
part of BoNT, which is a bacterial endotoxin that exerts its paralytic effect by delivering
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the LC protease into the cell. The specific location of cleavage is determined from which
serotype the LC is derived from and BoNT/A LC cleaves synaptosomal associated
protein of 25 kDa (SNAP-25) from the surface of the inner membrane of the neuron.7 The
cleavage occurs in the C-terminus (Gln197-Arg198) of SNAP-25 and the specificity of
this cleavage is driven in part by the binding of distal elements distal to the cleavage
site.154 BoNT/A LC is also part of BoTox, which is a carefully prepared and purified
form of BoNT/A that is the best available therapeutic agent for a variety of human
diseases due to a functional inhibition of cholinergic terminals.155
To this end, a variety of microsphere based protease assays for high-throughput
screening of protease activities have been developed.69,74 These assays, like other surface
based protease assays, have the advantage that they can use large protein substrates
containing distal binding elements. Inclusion of the distal site in HTS assays enables
discovery of novel inhibitors that target this critical protein-protein interaction.
Additionally, surface assays more closely mimic the natural surface based cleavage of
SNAP-25 by BoNT/A LC. Microsphere based protease assays may offer an attractive
version of these assays as they provide continuous time resolution and intrinsic resolution
of free vs. bound fluorophores from the surface.109 However, a complete demonstration
of their ability to provide accurate kinetic analysis has not yet been demonstrated.
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5.2 Materials and Methods
5.2.1 Materials
DNA oligonucleotide primers were synthesized by IDT (Coralville, IA) and Operon
(Huntsville, AL). Terrific broth (TB) was purchased from Fisher scientific (Pittsburg,
PA). Tris-base, Tween-20, Dithiothreitol (DTT), isopropyl-β-D-thiogalactopyranoside
(IPTG), Bovine Serum Albumin (BSA), Hepes Hemisodium Salt, Sodium Chloride,
Phosphate-buffered Saline (PBS), Carbenicillin, Chloramphenicol, and Biotin were
bought from Sigma-Aldrich Corporation (St. Louis, MO). BoNT/A LC was bought from
List Biological Laboratories (Campbell, CA). SoftLinkTM streptavidin resin was obtained
from Promega Corporation (Madison, WI). Streptavidin-coated microspheres were
obtained from Spherotech Corporation (Lake Forest, IL). Streptavidin-Cy3 conjugate was
bought from Invitrogen (Grand Island, NY).

5.2.2 Expression and Purification of SNAP-25 GFP
Protein substrate synthesis with enhanced green fluorescent protein (EGFP) at the Cterminal and biotinylated tag at the N-terminal has been performed previously.69 We have
described the expression and purification of biotinylated tag and GFP domain BoNT/A
LC substrate in our earlier work.74 Briefly, a single colony with plasmid of interest was
grown overnight in 3 mL Terrific broth (TB) media containing 50 µg/mL carbenicillin,
34 µg/mL chloramphenicol, then transferred to 250 mL TB 50 µg/mL carbenicillin, 34
µg/mL chloramphenicol, 40 µM biotin and grown at 37°C  until optical density at 600 nm
(OD600) reached 0.6-0.8. After, the cultures were induced with 100 µM IPTC and grown
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overnight at 30°C   in a shaking incubator (250 rpm). The overexpressed SNAP-25 GFP
protein with a biotinylated tag was purified by SoftLinkTM column with streptavidinbiotin system. The cultured cells were harvested by centrifugation at 3500 rpm on a
Beckman Avanti J-301 centrifuge for 30 min at 4°C and washed by water twice to
remove the biotin and were suspended in 40 mL lysis buffer (PBS+1 mM DTT). The
resuspended cells were sonicated in an ice bath for 15 min and centrifuged at 14,800 rpm
for another 30 min at 4°C. The clear supernatant was loaded onto a 5 mL SoftLinkTM
avidin resin at a flow rate of 1 mL/min at 4°C. The PBS buffer with 5 mM biotin was
used for eluting the protein from the column. Following, the eluted sample was dialyzed
with protease buffer (50 mM HEPEs, 100 mM NaCl, pH 7.4) for three times to remove
the free biotin. The purified protein was confirmed with sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The concentration was determined by
using A280 spectroscopic measurement and the calculated extinction coefficients.

5.2.3 Microsphere Based Protease Assays
To measure the minimal saturable concentration of biotinylated SNAP-25 GFP on 5
µm diameter streptavidin coated microspheres (SVP-50-5, Spherotech, Lake Forrest, IL),
the substrate was titrated in 500 µL reaction volumes with 1.72×105 microspheres/mL per
sample. After a one-hour incubation, all the microspheres were centrifuged at 14,800 rpm
in an Eppendorf mini-spin plus centrifuge with a F45-12-11 rotor for 1 min and washed
with protease buffer (50 mM HEPES, 100 mM NaCl, 1 mg/mL BSA, 0.025% Tween-20,
pH 7.4) three times to remove the free substrate. Single point measurements were done
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by flow cytometry on an Accuri C6 flow cytometer with the GFP fluorescent signal
measured in the FL1 detection channel.
Then 25 nM SNAP-25 GFP was associated with the diameter of 5 µm streptavidin
labeled microspheres in the protease buffer. Protease concentrations were 0， 2.5， 5，
10, 25, 50, 100, 200, 300 and 500 nM in total reaction volume of 500 µL, respectively.
The substrate bound microspheres were prepared with an excess of 14 µL or 66 µL to be
delivered at the delivery rate of the flow cytometer (14 µL/min or 66 µL/min) over the 60
seconds required to establish a baseline. After 1 minute the tube was removed from the
Accuri C6 flow cytometer (BD Biosciences, San Jose, CA) and BoNT/A LC dissolved in
protease buffer was added to bring the final volume to 500 µL at the indicated
concentrations. Upon protease addition the sample was mixed by vortexing for 5 seconds
to start the cleavage reaction. All the samples were run continuously for 8 or 10 min. The
32 bit time resolution of the Accuri C6 ensured that we had 100 ms temporal resolution,
which was more than sufficient for this assay.

5.2.4 Dead Time Measurement of Accuri C6 Flow Cytometer
For the analysis of the time delay between the addition of the protease and the
appearance of beads exposed to protease in the flow cytometer, calibration beads with
GFP fluorescence were added at the 60s time point when the blank beads without any
fluorescence were running at fast, medium and slow flow rates of the Accuri. The
fluorescence signals at each time point were collected and analyzed to obtain the dead
time between blank beads and fluorescence beads.
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5.3 Results and Discussion
5.3.1 Titration of Binding of SNAP-25 GFP to The Surface of Microspheres.
We constructed the protease substrate with biotinylation tag at N-terminal and GFP
domain at C-terminal which was bound to streptavidin-coated microspheres. The specific
binding between biotinylated SNAP-25 GFP and streptavidin-coated microspheres was
performed based on the titration of biotinylated SNAP-25 GFP by increasing the
substrate concentration (Figure 5.1). Microspheres were incubated at 25°C for 1 hour in
the presence or absence of biotin. In the presence of biotin, there was almost no
fluorescence signal due to biotin blocking the binding of SNAP-25 GFP to the
streptavidin-coated microspheres (data not shown). The difference in fluorescence
intensity between unblocked and blocked samples was calculated to determine the
specific binding of biotinylated SNAP-25 GFP to microspheres. Fitting of binding data to
a hyperbolic curve resulted in an estimated dissociation constant (KD) of 7 nM for the
biotin-streptavidin interaction. The curve of bound substrate concentration indicated that
the concentration of substrate on the microsphere was low compared with traditional
solution assay. At this point, the microsphere-based assay provides the advantage of
saving substrate cost.

81
	
  

Figure 5.1 Equilibrium binding of SNAP-25 GFP on microspheres with a hyperbolic
fitting

curve.

Streptavidin-coated

microspheres

were

incubated

with

varying

concentrations of SNAP-25 GFP and fluorescence on microspheres was measured by
flow cytometry.
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5.3.2 BoNT/A LC Cleavage of Full-length SNAP-25 Fusion Proteins from A
Microsphere Surface
Our microsphere assay has been described in detail previously,74 but in brief this assay
uses titration of biotinylated SNAP-25 fusion protein concentration to determine the
minimal saturating concentration for protease cleavage. The affinity of binding of
biotinylated SNAP-25 GFP to streptavidin-coated microspheres is high with a
dissociation constant (KD) of 7 nM. This tight binding ensures that slow dissociation of
the full-length substrate does not contribute to the observed cleavage rates (Figure 5.2).
This was confirmed by showing constant fluorescence of the microsphere prior to our
kinetic assay (Figure 5.2). Protease was added at known concentrations at 60 seconds,
which resulted in a rapid loss of microsphere fluorescence. BoNT/A LC has been shown
to be highly specific for our full-length SNAP-25 substrate in this assay.74 Additionally,
the intrinsic ability of a flow cytometer to resolve free vs. bound fluorescent molecules
on particle surfaces eliminates the need for wash steps to measure the loss of microsphere
fluorescence due to protease cleavage.156 This property makes it simple to measure the
both the time dependent fluorescence loss (Figure 5.2) and to determine the original
fluorescence intensity of SNAP-25 GFP on the microspheres as well as the remaining
fluorescence on microspheres after protease cleavage. Microsphere fluorescence intensity
does not approach zero due to a small portion of the SNAP-25 GFP that may be nonspecifically associated or adsorbed to the surface.74
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Figure 5.2 The fluorescence measurement of cleavage from microspheres vs. time. The
full-length protease substrate was designed with the biotinylation tag at the N-terminal
(brown oval) and the GFP domain at the C-terminal (green sun) separated by full-length
SNAP-25 (brown cylinder) which is attached to streptavidin (blue crescent)-coated
microspheres (gray circle). The fluorescence of GFP was measured before protease
cleavage as baseline, then BoNT/A LC (red pie) was added at 60 s for cleavage, with the
fluorescence change detected with increasing time.
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5.3.3 Kinetics of BoNT/A LC Cleavage from The Microsphere Surface
To determine the rate of cleavage vs. time, BoNT/A LC with various concentrations
was incubated with SNAP-25 labeled microspheres (Figure 5.3A). The apparent rate of
cleavage had clear concentration dependence (Figure 5.3B). In the simplest interpretation
of such kinetics, it is viewed that the increasing concentrations of protease achieve rapid
binding of the protease to the substrate and the forward cleavage reaction approaches that
of the rate limiting step, which leads to an estimate of the rate limiting step of
approximately 0.3 s-1 for the microsphere assay. This is a similar approach that was
effective for nuclease cleavage of DNA from microspheres.149 A more comprehensive
view of this data can make use of the EQSS kinetic model, which is valid under the
conditions shown in Equation 1.135

![!! !" ]
!! ![!! ]

≪1

(1)

Where f is the surface area per unit volume of the assay, [S0SP] is the surface density of
the substrate molecules, Km is the Michaelis constant of the reaction, and [E0] is the total
enzyme concentration.
Given that we have 106 microspheres/mL and that the microspheres are 5 µm in
diameter, the f value is roughly about 0.8 cm-1. Considering the protein is 67 kDa, it
would have a minimal radius of ~2.5 nm if packed as sphere. Maximal packing of
spheres occurs in a regular hexagonal configuration, where each hexagon would have an
area of ~2.2×10-13 cm2 to fully contain a 2.5 nm radius protein leading to a maximal
estimate of 4.6×1012 proteins per cm2 for our substrate. Given the f value of 0.8 cm-1 then
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f[S0]=3.7×1012 proteins/cm3 or 3.7×1015 proteins/L or 6 nM. Of course a reasonable
assumption is that this level of packing is not achieved and that some lower fraction of
surface coverage is achieved, which typically is about 10-25% of maximal packing.
Given this a reasonable estimate of f[S0] is roughly 1 nM. Thus if the Km of a reaction is
100 nM or greater, the conditions of Eq. 1 are easily satisfied for the microsphere-based
assay. Using the microsphere system, any reaction that has a Km greater than 100 nM
satisfies the requirements of equation 1 and results in an EQSS system. For EQSS
systems it is possible to make a pseudo steady state assumption that relates initial
velocities to enzyme concentration. At this condition, the proposed reaction scheme is

E+S

k1
k-1

ES

kcat

E+P

Where, the total substrate concentration [S] can be accounted for both free substrate [S]f
and enzyme-substrate complex [ES], which is defined as:

[ S ] = [ S ] f + [ ES ] , (2)
Here, [ES] depends on the rate of formation of the complex (k1) and the rate of loss of the
complex (k-1 and kcat). Also, assuming that the amount of enzyme bound to substrate does
not change the free enzyme concentration ([E]=[E]f). The rate equations for these two
processes are thus given by:

d [ ES ]
= k 1[ E ][S ] f
dt
, (3)
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− d [ ES ]
= (k − 1 + kcat )[ES ]
dt
, (4)
Under steady state conditions there two rates must be equal, hence:

k 1[ E ][S ] f = (k − 1 + kcat )[ES ]

, (5)

This equation can be rearranged as:

[ ES ] =

[ E ][S ] f
(k − 1 + kcat ) / k 1 , (6)

Also, the term Km is defined as:

Km =

k − 1 + kcat
k1
, (7)

The equation (7) could be expressed as:

[ ES ] =

[ E ][S ] f
Km , (8)

From equation (2), the [S]f can be replaced by ([S]-[ES]). With this substitution, equation
(8) can be recast as:

[ ES ] =

[ E ][S ]
Km + [ E ] , (9)

Also, the pseudo-first-order progress curve for an enzymatic reaction can be described by:

v = kcat[ES ]

, (10)

Combining equations (9) and (10), the velocity could be obtained as:
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v=

kcat[ E ]
[S ]
Km + [ E ] , (11)

This enables simple determination of both kcat (k2) and Km from the fit of this equation to
the data (Figure 5.3B). This approach provides an estimate of 0.52 s-1 ± 0.15 s-1 for kcat,
0.38 ± 0.20 µM for the Km, and 1.4×106 M-1 s-1 for the specificity constant (kcat/ Km).
While these rate measurements are of clear value, factors such as substrate surface
density and transport effects near microsphere surfaces, such as slowed product release,
could result in reduced accuracy for these values.135, 157
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Figure 5.3 Kinetic analysis of BoNT/A LC based on microsphere. A. BoNT/A LC
cleavage kinetics with increasing enzyme concentration, which are shown in the legend
where the numbers indicate the concentration of BoNT/A LC in nM. The fitted lines are
shown in matching colors on the plot. B. Plot of kobs vs. BoNT/A LC concentrations,
from which kcat and Km were calculated by hyperbolic fitting curve, kcat[E]/(Km+[E]). This
fit provided an estimate of 0.52 ± 0.15 s-1for kcat and 0.38 ± 0.20 µM for Km.
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5.3.4 Dead Time Measurement of Accuri
In order to determine the time delay of Accuri C6 flow cytometer, I prepared blank
beads and fluorescence beads labeled with SNAP-25 GFP. The fluorescent beads were
added at 60-second after the blank beads to determine the time between bead addition and
subsequent detection in the Accuri flow cytometer. All the calibrations were performed at
different flow rates from slow speed (14 µL/min) to fast speed (66 µL/min) of the Accuri.
The fluorescence signals at different time points were collected and analyzed to show that
the dead times were about 9.6 s for the slow rate and 2.5 s for the fast rate, respectively
(Figure 5.4). The prolonged dead time at the slow flow rate indicated that the calculated
cleavage rates at higher protease concentrations were artificial results. In addition, the
determination of the kinetic constants was not correct due to dead time limitations.
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Figure 5.4 Dead time measurement of Accuri at slow and fast flow rates. A. The display
of fluorescence and events at different time points at the slow flow rate. B. The display of
fluorescence and events at the fast flow rate. C. The dead time determination of 9.6 s at
slow flow rate. D. The dead time of 2.4 s at fast rate.
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5.3.5 Protease Cleavage Measurement Using Accuri at Fast Flow Rate
Based on the determination of dead time of Accuri, I repeated the protease cleavage
assays with different enzyme concentrations from 0 nM to 500 nM at the fast flow rate
(66 µL/min) to obtain a better estimate of the true cleavage rates (Figure 5.5A). Due to
the limitation of enzyme concentrations, I didn’t obtain the saturated state to determine
the kinetic constants including kcat and Km values, however, I still gained the kcat/Km value
of 9×105 M-1s-1 with linear fitting the data points (Figure 5.5B). The smaller catalytic
constant obtained here also indicated that we didn’t determine the correct kinetic
constants owing to the long dead time at slow flow rate. At this point, I have to increase
the substrate concentration in order to carry out kinetic study of the protease on surface
by flow cytometer since the low surface to volume ratio of microspheres limits the
substrate concentration in nanomolar range. Therefore, it is very necessary to develop
nanosphere-based protease assay for kinetic studies with increasing substrate
concentrations. Basically, the nanospheres lead to the higher surface to volume ratio that
results in higher substrate concentrations and may provide enough substrate for protease
cleavage.
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Figure 5.5 Protease cleavage assay at fast flow rate. A. The real cleavage measurement
with increasing protease concentrations to 500 nM. B. The linear fitting of observed rates
vs. protease concentrations.
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5.4 Conclusion
We developed real-time measurements of BoNT/A LC by using the full-length
fluorescent substrate on microspheres. Even though we didn’t determine the main kinetic
constants based on microspheres, it should be noted that this approach may or may not be
generally applicable and that structural features of SNAP-25, such as the proximity of the
N and C termini may make this a unique assay for the BoNT/A LC-SNAP25-GFP
complex. The nanosphere-based protease cleavage assay will be employed to determine
the key kinetic constants due to higher substrate concentrations. The successful use of
surface-based protease assay along with their speed and simplicity indicate that these
approaches will be highly attractive for HTS for inhibitors of proteases.
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Chapter 6
Nanosphere-based Kinetic Analysis of Botulinum Neurotoxin Type A
Light Chain
6.1 Introduction
Proteases are heavily involved in many normal biological processes as well as in
diseases, including cancer, stroke and infection. As a result, protease activity is a widely
studied topic and protease activity assays have significant medical relevance. Presently,
there are a wide variety of protease assays. However, all current assays have one or more
limitations that include use of small substrates, use of low substrate concentrations, and
low multiplexing ability.
We have developed a multiplexed microsphere protease assay that can detect the
activity of several metalloproteases simultaneously.69 Multiplexed protease assays are
attractive because many proteases exist as protein families operating in similar fashion
across related disease, pathogens, and cellular processes.158 For example, each of the
seven types of Botulinum neurotoxin light chain proteases (A – G) recognizes different
aspects of one protein of the SNARE complex.20 We have demonstrated that multiplex
assays can analyze many substrates and proteases simultaneously, making the discovery
of lead compounds for a protease family faster and less labor intensive.69,

74
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importantly, the microsphere assay uses large protease substrates containing exosites that
are required for full protease activity. This is an advantage of surface based protease
assays, as typical FRET peptide assays cannot utilize large substrates and are not
effective for studies of many protease substrate interactions. Furthermore, multiplexing
using microsphere arrays makes it possible to screen multiple proteases, interactions of a
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single protease with multiple substrates, or a combination of both.74 However, protease
assays must provide substrates at saturating concentrations to determine steady state
kinetics routinely used to evaluate kinetics and lead compounds.
While planar and microsphere assays are amenable to multiplexing and incorporation
of biomimetic membranes, practical considerations of surface area to reaction volume
(SA/V) ratios limit substrate concentrations to the nM range. For a microsphere with
radius 5 µm (surface area of roughly 3 x 108 nm2), a typical 60 kDa globular protein with
a cross-sectional area of ~20 nm2, a typical microsphere maximally has ~1 x 106 proteins
attached to its surface. This microsphere has a volume of 5.2 x 10-7 µL, so for a practical
analysis limit of 10% microsphere to reaction volume ratio, the maximum usable
microsphere concentration is ~190,000 microspheres/µL. This value and the number of
surface proteins predict a maximum substrate concentration of about 300 nM for
reactions occurring on this microsphere. Such conditions are not saturating for most
proteases and prevent the determination of standard kinetic parameters (kcat, Km and Ki)
for activity and inhibitor comparisons. If we neglect the effects of the analytical volume
and use the same ratio of total particle volume to reaction volume, the use of nanospheres
would make it possible to increase surface bound substrate to saturating concentrations
(~60 µM) for low affinity proteases. The increase in concentration is due to the simple
inverse relationship between surface area to volume ratio of a sphere and the radius of a
sphere (SA/V=3/radius). By decreasing the diameter of our spheres from 2.5-10 µm to
25-100 nm, while maintaining the same particle volume to reaction volume ratio, we
increase the relative surface area and the effective substrate concentration in a reaction by
100 fold. The use of nanospheres makes it possible to increase surface bound substrate to
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saturating concentration for low affinity proteases. The development of a nanospherebased protease assay enables the use of full-length protease substrates, multiplexed assays,
and, most importantly, provides high substrate concentrations in a surface assay format.
To create the nanosphere assay, which is based on our microsphere protease assay
platform, I hypothesize that the use of nanospheres bearing surface bound substrates will
retain the advantages of microsphere assays yet provide high surface area to volume ratio
that will enable substrate concentrations in the µM range. To demonstrate this approach I
implemented our nanosphere protease assay using the toxin protease models to first
demonstrate the concept and then with BoNT/A LC through 380 nm streptavidin-coated
nanospheres. Cleavage from the surface of the nanosphere was detected via observing
nanosphere fluorescence changes on a flow cytometer.

6.2 Materials and Methods
6.2.1 Materials
BoNT/A LC was bought from List Biological Laboratories (Campbell, CA). 380 nm
Streptavidin-coated nanospheres were obtained from Spherotech Corporation (Lake
Forest, IL). Streptavidin-Cy3 conjugate was bought from Invitrogen (Grand Island, NY).
Bovine Serum Albumin (BSA), Hepes Hemisodium Salt, Sodium Chloride, Phosphatebuffered Saline (PBS) and Biotin were bought from Sigma-Aldrich Corporation (St.
Louis, MO).
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6.2.2 Prepare Fluorescent Fusion Protease Substrates
We developed fusion protein substrates specific for BoNT/A LC, which was SNAP-25
GFP containing a biotinylation tag at N-terminal and a GFP domain at C-terminal. The
detailed construction was described in Chapter 4. The substrates would be cleaved by
proteases both in solution and on nanospheres. These nanospheres are commercially
available and offer an effective method to explore the utility of nanosphere based
protease assays.

6.2.3 Determine Events Rate by BD FORTESSA Flow Cytometry
The nanospheres with the concentration of 3.3×1011 nanospheres/mL were diluted into
varied concentrations: 1010, 109, 108, 107 and 106 per mL. Each sample was tested by
FORTESSA flow cytometer triggering on the fluorescence of nanospheres in the PE-Cy5
detection channel (667 nm). The event rates were determined by dividing the number of
events with 40 seconds at different particle concentrations.

6.2.4 Titration of Protease Substrate on Nanospheres
To measure the minimal saturable concentration of biotinylated SNAP-25 GFP on 380
nm streptavidin coated nanospheres, the substrate at appropriate concentrations was
titrated in 500 µL reaction volumes with 1×108 nanospheres/mL per sample. To
determine the specific binding between substrate and nanospheres, the unblocked sample
was carried out with nanospheres and substrate for one-hour incubation at room
temperature. In addition, the blocked sample was carried out that the nanospheres were
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incubated in the presence of 80 mM biotin for 30 min and protein substrate was added for
additional one-hour incubation at room temperature. After incubation, all the nanospheres
were centrifuged at 14,800 rpm in an Eppendorf mini-spin plus centrifuge with a F45-1211 rotor for 1 min and washed with protease buffer (50 mM HEPES, 100 mM NaCl, 1
mg/mL BSA, 0.025% Tween-20, pH 7.4) three times to remove the free substrate. Single
point measurements were done by flow cytometry on a BD FORTESSA flow cytometer
with the GFP fluorescent signal measured in the FITC (520 nm) detection channel.

6.2.5 Nanosphere-based Protease Cleavage Assay
500 nM SNAP-25 GFP was associated with 380 nm streptavidin labeled nanospheres
in protease buffer. Protease concentrations were 0,5,10, 20, and 40 nM and the total
reaction volume was 500 µL for each sample, respectively. The substrate bound
microspheres were prepared with an excess of 12 µL volume to be delivered at the
delivery rate of 12 µL/min on the flow cytometry over the 60 seconds required to
establish a baseline. After one minute the tube was removed from the BD FORTESSA
flow cytometer (BD Biosciences, San Jose, CA) and BoNT/A LC in the protease buffer
was added to bring the final volume to 500 µL at the indicated concentrations. Upon
protease addition the sample was mixed to start the cleavage reaction. All the samples
were run continuously for 8 or 10 min. All the mean FITC fluorescence values were
converted into normalized fluorescence values by dividing the data point after adding
BoNT/A LC by the average fluorescence values of the first 60 seconds.
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6.2.6 Size Measurement of Nanospheres
In order to determine the size of nanospheres, we measured the sizes of the nanospheres
based on different concentration as described in event rate determination. The
measurement was carried out using dynamic light scattering method.

6.3 Results and Discussion
6.3.1 Predicted and Measured Event Rates
Using BD FORTESSA flow cytometer, we assumed the interrogation volume of this
machine with a diameter of 5 µm and height of 10 µm, and predicted the event rates at
slow flow rate (12 µL/min) against various particle concentrations (Figure 6.1 Red line).
In addition, we determined the real event rates by triggering on the fluorescence of the
nanospheres. The observed rates were plotted against particle concentrations (Figure 6.1
Blue line). The results showed that the observed event rates were about 103 fold less than
predicted rates, which meant not only single nanosphere but also doublets or aggregates
may go through the laser beam. Both linear fitting curves displayed the similar slopes that
also indicated that we successfully triggered on the fluorescence from nanospheres by
flow cytometry. At this point, we would like to perform the substrate titration on
nanospheres in order to obtain minimal saturation concentration for the protease cleavage
assay to determine the kinetic constants.
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Figure 6.1 Predicted and observed event rates are shown as red squares and blue
diamonds, respectively.
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6.3.2 Titration of SNAP-25 GFP on 380 nm Nanospheres
The specific binding between biotinylated SNAP-25 GFP and streptavidin-coated
nanospheres was performed based on the titration of biotinylated SNAP-25 GFP by
increasing the substrate concentration (Figure 6.2). The results of block titration showed
slightly increased fluorescence signal due to the biotin bound to streptavidin-coated
nanospheres. The difference of fluorescence values between unblock and block samples
was calculated to determine the specific binding of biotinylated SNAP-25 GFP to
nanospheres. The curve of bound substrate concentration illustrated that the concentration
of substrate on the nanospheres was increased to the micromolar range compared with the
microsphere-based titration (Chapter 5). Here, we didn’t obtain the saturated state owing
to the limitation of substrate concentrations. However, the titrated results showed that the
biotinylation-tag SNAP-25 GFP was successfully bound to the nanospheres and the
fluorescence on the nanospheres was detected by flow cytometry.
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Figure 6.2 Titration of SNAP-25 GFP on nanospheres. The streptavidin-coated
nanospheres were incubated with varied concentrations of SNAP-25 GFP and
fluorescence on nanospheres was measured by flow cytometry.
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6.3.3 Protease Cleavage Assay on Nanospheres
In this case, we detected nanosphere presence via intrinsic nanosphere fluorescence to
trigger collection. Protease activity was detected as loss of GFP fluorescence from the
nanosphere. To make this assay possible, we needed to ensure that I only had about 10%
occupancy on average within the detection volume of the FORTESSA, which essentially
a 10 µm high by 5 µm diameter cylinder (defined by the laser spot size and the sample
stream diameter). This volume (~2 x 10-10 mL) requires me to uses no more than about 2
x 109 nanospheres/mL.
The cleavage activity of BoNT/A LC was measured based on the fluorescence change
on nanospheres. With the addition of the protease, the loss of fluorescence on the
nanospheres was detected by flow cytometry. The cleavage of BoNT/A LC against
SNAP-25 GFP occurred very quickly in first 200 seconds and achieved a steady state
with extended time. The kinetics of protease cleavage were then shown as normalized
fluorescence vs time with a series of BoNT/A LC concentrations (Figure 6.3A). At low
concentrations of protease, the cleavage traces of BoNT/A LC against substrate were
slow with increasing time. Then the obvious cleavage was detected

with higher

concentrations of BoNT/A LC. In nanosphere-based assay, the SNAP-25 GFP
concentration was much less than the Km, the loss of substrate was still considered as a
function of time under first-order reaction. Assuming that nanosphere fluorescence is
proportional to concentrations, the observed rates of cleavage were obtained from
exponential fitting curves and plotted against the concentrations of BoNT/A LC (Figure
6.3B). These results showed that the cleavage rates depended on the concentrations of
BoNT/A LC and approached a saturating rate at higher concentrations. Therefore, the
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faster rates with higher BoNT/A LC concentrations were obtained because the enzyme
adsorbed to substrate bound nanospheres at high cocentrations retained a significant
fraction of their solution activity.159
While we have performed my current assays in real time using 108 nanospheres/mL
that only provides nM concentrations, future assays could be performed at high
nanosphere concentrations as high as 1013 nanospheres/mL. These assays could not be
performed real time, we will perform the protease reaction by quenching cleavage of the
metalloprotease via chelator addition, and then dilute to analyze on the flow cytometer.
This will allow me to perform reactions with surface bound substrate at the concentration
of 2 µM, which would not be possible using microspheres. We will use this nanospherebased assay to determine the Km and kcat for each of our proteases. We will also use these
parameters as a guideline to develop end point assays for high throughput screening.
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Figure 6.3 Protease cleavage of SNAP-25 on nanospheres. A. BoNT/A LC cleaved
SNAP-25 with increasing protease concentrations. BoNT/A LC concentrations were 0, 5,
10, 20 and 40 nM. B. Plot of observed rates against BoNT/A LC concentrations.
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6.3.4 Size Measurement of Nanospheres
To measure the size of our nanospheres, dynamic light scattering has been used to
determine the size distribution of the particles. The nanospheres with concentrations of
1010, 109, 108, 107 and 106 particles/mL were tested here. The optimal concentration of
108 particles/mL showed the best radius results of the nanospheres in Figure 6.4. From
the result, the main radius is around 178 nm representing a diameter of 356 nm
nanospheres that is very close to the size from the technical instruction of the
nanospheres we have purchased. In addition, there are three other radii including 3 nm,
2263 nm and 147823 nm. The 3 nm radius is probably the noise of the instrument, but the
2263 and 147823 nm radii may represent the presence of aggregates. This result also
confirmed that the observed event rates we obtained previously were much slower than
predicted rates triggering on fluorescence by flow cytometry because of low sensitivity of
the instrument or aggregating of nanospheres.
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Figure 6.4 Dynamic light scattering measurements of nanospheres to obtain the size.
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6.4 Conclusion
In this chapter, we have developed the nanosphere-based protease assay that provides
high surface area to volume ratio enabling substrate concentrations in the µM range for
kinetic studies. We have performed the protease cleavage assay on nanospheres with
increased substrate concentration. In addition, the exact kinetic model should be
considered here to determine the key kinetic constants of BoNT/A LC on nanospheres.
These kinetic pathways will be combined with mutagenesis studies and any discovered
small molecule inhibitors to explore how proteases and their substrates interact.
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Chapter 7
Conclusions and Future Directions
7.1 Conclusions
7.1.1 Parallel Protease Assay Using Suspension Microsphere Arrays for Highthroughput Screening
In this work, we have successfully developed microsphere-based protease assay using
384 and 1536-well plate high-throughput screening to identify potential inhibitors for
Bacillus anthracis lethal factor (LF) and Botulinum neurotoxin type A & F light chains
(BoNT/A &F LCs) via flow cytometry. We have demonstrated the construction of fulllength protease substrates with a biotinylation tag and N-terminal and a GFP domain at
C-terminal. We have performed the multiplexed protease assay by running several
proteases simultaneously in the same reaction volume since each protease can
specifically recognize and cleave their own substrates. The identification of inhibitors by
high-throughput screening has been described in Chapter 3 from Prestwick chemical
library and NIH chemical library.

7.1.2 Selection of Potential Inhibitors for Bacterial Metalloproteases
In my research, we have identified several specific inhibitors for lethal factor, BoNT/A
LC. In Chapter 3, riboflavin has been distinguished from 1128 compounds as a specific
inhibitor for lethal factor with the IC50 values around 15 µM in both microsphere-based
and FRET peptide solution assays. Later, we have found several inhibitors against LF,
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BoNT/A & F LCs from 350,000 chemical library using 1536-well plates. These
compounds showed great inhibition with the IC50 values lower than 20 µM for the
proteases. The multiplexed microsphere-based protease assay for high-throughput
screening have demonstrated a great ability to screen several protease simultaneously that
dramatically reduces screening labor and cost, immediately provides information on
specificity of an inhibitor and displays an promising approach for study of many protein
members from a family of related proteases simultaneously.

7.1.3 FRET Solution Assays for Protease Kinetic Analysis
In my work, we have developed FRET solution assays containing both peptide and
full-length substrates. We have bought commercially available FRET peptides including
MAPKKide and SNAPtide for LF and BoNT/A LC to determine the IC50 values of
potential inhibitors identified in microsphere-based assay. Due to the limited substrate
dissolved in solution, we didn’t obtain the important kinetic constants like kcat, Km or Ki
values. In addition, we designed a full-length FRET substrate that contained a FRET pair
of GFP and Cy3 linked by a biotinylation-tag full-length protease substrate conjugated to
Cy3 labeled streptavidin. We have employed these substrates to evaluate the inhibitors
and demonstrate the kinetic studies for BoNT/A LC. Both substrates have been used to
confirm and estimate the inhibitors for determination of specific inhibition. Compared the
results with those obtained from microsphere-based assay, the identification of specific
inhibitors indicates the great importance of distal events in the interaction between
proteases and substrates. Blocking the binding of proteases and substrates at exosites has
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been proved to inhibit the activity of a protease. We have determined the key kinetic
constants of BoNT/A LC including kcat, Km and kcat/Km values using full-length substrates.
We have also determined the inhibition mechanisms of some specific compounds against
BoNT/A LC. All of them are competitive inhibitors the Ki values lower than 5 µM. These
kinetic constants would provide more information of BoNT/A LC and its inhibitors.

7.2 Future Directions
7.2.1 Nanosphere-based Protease Assay
While planar and microsphere assays are amenable to multiplexing and incorporation
of biomimetic membranes, practical considerations of surface area to reaction volume
(SA/V) ratios limit substrate concentrations to the nM range. The use of nanospheres
would make it possible to increase surface bound substrate to saturating concentrations
(~60 µM) for low affinity proteases. The increase in concentration is due to the simple
inverse relationship between surface area to volume ratio of a sphere and the radius of a
sphere (SA/V=3/radius). By decreasing the diameter of our spheres from 2.5-10 µm to
25-100 nm, while maintaining the same particle volume to reaction volume ratio, we can
increase the relative surface area and the effective substrate concentration in a reaction by
100 fold. We estimate that each nanosphere will bear between 50 and 200 molecules of
most substrates, which will allow concentrations in the µM range when 1 x 1013
nanospheres per mL are used. These nanospheres are commercially available and offer an
effective method to explore the utility of nanosphere-based protease assays. The use of
nanospheres will make it possible to increase surface bound substrate to saturating
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concentration for screening of low affinity proteases. The development of a nanospherebased protease assay will enable the use of full-length protease substrates, multiplexed
assays, and, most importantly, provide high substrate concentrations in a surface assay
format. We will optimize and configure the assay for screening format in 384-well plates
for demonstration screening of the Prestwick library (1280 off-patent chemical
compounds). This effort will consist of optimizing endpoint protease assays in small
volumes and then analyzing on the HyperCyt® flow cytometer.

7.2.2 Future Drug Targets: Matrix Metalloproteases
Of specific interest here is that overexpression of matrix metalloproteases (MMPs) is
suggested to lead to tissue degradation and pathological disorders such as arthritis and
metastatic cancer.160,161 The consequences of deregulation of MMP activity can include
cancer-associated processes like tumorigenesis and tumor neovascularisation, invasion
and metastasis, as well as apoptosis, intestinal defense activation and pathologies of the
nervous systems.162 We will implement our nanosphere-based protease assay using our
toxin protease models to first demonstrate the concept and then with MMPs that have
reduced specificity and affinity for their substrates, which necessitates the use of higher
substrate concentrations to detect protease activity. As MMPs play important roles in
many forms of cancer, the discovery of specific MMP inhibitors is very clinically
relevant. We will design fusion protein substrates for several MMPs (MMP-2, 3, & 9)
and attach them to the surface of commercial nanospheres. We will design the
constructions of MMP substrates: cystatin C for MMP2, connective tissue growth factor
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(CTGF) for MMP3 and amyloid beta A4 protein for MMP9.163 Gene sequences of all the
substrates

can

be

synthesized

by

Blue

Heron

Biotech

Company

(https://wwws.blueheronbio.com). Cleavage from the surface of the nanosphere will be
detected via observing fluorescence changes from nanospheres on a flow cytometer.
Once developed, we will optimize the assay for use in high throughput flow cytometry
screening and demonstrate its effectiveness by screening the Prestwick library of
chemical compounds for potential MMP inhibitors. Identifying more specific inhibitors
will be important as, unfortunately, existing MMP inhibitors have not performed very
well in clinical trials, so selection of potential MMP inhibitors and development of novel
applications of these inhibitors will be potentially very useful for treatment of MMP
related diseases such as cancer metastasis.

7.2.3 High-throughput Screening and Kinetic Studies of MMPs
We will optimize and configure the assay for screening format in 384-well plates for
demonstration screening of the Prestwick library (1280 off-patent chemical compounds).
This effort will consist of optimizing endpoint protease assays (MMPs are Zn-dependent
metalloproteases, EDTA is used to stop the reaction at a given time) in small volumes
and then analyzing on the HyperCyt® flow cytometer. This demonstration screen will be
used as preliminary data for subsequent funding via funding mechanisms available to
collaborators of the UNM Center for Molecular Discovery. We will also use the
nanosphere-based assays to determine inhibition modes and kinetic parameters (Ki).
These kinetic pathways will be combined with mutagenesis studies and any discovered
small molecule inhibitors to explore how proteases and their substrates interact.
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List of Appendices
Appendix 1. DNA Sequence of VMAP-2 with Restriction Sites (SacI and BamHI)
GAGCTCATGTCTGCTACCGCTGCCACGGCCCCCCCTGCTGCCCCGGCTGGGG
AGGGTGGTCCCCCTGCACCCCCTCCAAACCTCACCAGTAACAGGAGACTGCA
GCAGACCCAGGCCCAGGTGGATGAGGTGGTGGACATCATGAGGGTGAACGT
GGACAAGGTCCTGGAGCGAGACCAGAAGCTGTCGGAGCTGGACGACCGTGC
AGATGCACTCCAGGCGGGGGCCTCCCAGTTTGAAACAAGCGCAGCCAAGCTC
AAGCGCAAATACTGGTGGAAAAACC TCAAGATGATGTCTAGGATCC

Appendix 2. Identified Inhibitors for Botulinum Neurotoxin Type A Light Chain in
Microsphere-based High-throughput Screening
Compound

Structure

IC50 value

CID 4464849
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4.9

	
  
	
  

CID 12006136

17.8

	
  

117
	
  

	
  

CID 702952

0.6

	
  

CID 1329560

6.1

	
  
	
  

CID 2827281

0.3

	
  

CID 3297919

1
	
  

118
	
  

	
  

CID 5056211

4

	
  

CID 1255814

1.5
	
  

CID 2214213

5.8
	
  

CID 1299052

1.5
	
  
	
  

CID 2858748

7.5

	
  

119
	
  

Appendix 3. Identified Inhibitors for Botulinum Neurotoxin Type F Light Chain in
Microsphere-based High-throughput Screening
Compounds

Structure

IC50 value
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Appendix 4. Identified Inhibitors for Bacillus Anthracis Lethal Factor in
Microsphere-based High-throughput Screening
Compound

Structure

CID 3335282
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